US20220194928A1 - Novel n-acylurea derivative and composition comprising same for prevention or treatment of cardiovascular disease - Google Patents
Novel n-acylurea derivative and composition comprising same for prevention or treatment of cardiovascular disease Download PDFInfo
- Publication number
- US20220194928A1 US20220194928A1 US17/692,111 US202217692111A US2022194928A1 US 20220194928 A1 US20220194928 A1 US 20220194928A1 US 202217692111 A US202217692111 A US 202217692111A US 2022194928 A1 US2022194928 A1 US 2022194928A1
- Authority
- US
- United States
- Prior art keywords
- phenyl
- alkylene
- alkoxy
- acetamide
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 14
- 230000002265 prevention Effects 0.000 title abstract description 9
- 239000000203 mixture Substances 0.000 title description 17
- 238000000034 method Methods 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 93
- 239000012434 nucleophilic reagent Substances 0.000 claims description 62
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 40
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 31
- WWEINXQNCAWBPD-UHFFFAOYSA-N 3-fluoropyridin-2-amine Chemical compound NC1=NC=CC=C1F WWEINXQNCAWBPD-UHFFFAOYSA-N 0.000 claims description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 27
- RUTNWXBHRAIQSP-UHFFFAOYSA-N 4-bromo-3-methoxyaniline Chemical compound COC1=CC(N)=CC=C1Br RUTNWXBHRAIQSP-UHFFFAOYSA-N 0.000 claims description 24
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical group 0.000 claims description 18
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 18
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
- 125000004076 pyridyl group Chemical group 0.000 claims description 15
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 15
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 claims description 14
- MOVMEFHWBOWMFU-UHFFFAOYSA-N 2-chloroacetyl isocyanate Chemical compound ClCC(=O)N=C=O MOVMEFHWBOWMFU-UHFFFAOYSA-N 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- 125000001041 indolyl group Chemical group 0.000 claims description 11
- 125000002757 morpholinyl group Chemical group 0.000 claims description 11
- 125000004193 piperazinyl group Chemical group 0.000 claims description 11
- FTZQXOJYPFINKJ-UHFFFAOYSA-N 2-fluoroaniline Chemical compound NC1=CC=CC=C1F FTZQXOJYPFINKJ-UHFFFAOYSA-N 0.000 claims description 10
- FIIDVVUUWRJXLF-UHFFFAOYSA-N 4-phenylmethoxyaniline Chemical compound C1=CC(N)=CC=C1OCC1=CC=CC=C1 FIIDVVUUWRJXLF-UHFFFAOYSA-N 0.000 claims description 10
- OCKPROYBCPQWJO-UHFFFAOYSA-N acetyl isocyanate Chemical compound CC(=O)N=C=O OCKPROYBCPQWJO-UHFFFAOYSA-N 0.000 claims description 10
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 claims description 10
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 10
- UIXTUDLFNOIGRA-UHFFFAOYSA-N n-carbamoyl-2-chloroacetamide Chemical compound NC(=O)NC(=O)CCl UIXTUDLFNOIGRA-UHFFFAOYSA-N 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 9
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 9
- QWBBPBRQALCEIZ-UHFFFAOYSA-N 2,3-dimethylphenol Chemical compound CC1=CC=CC(O)=C1C QWBBPBRQALCEIZ-UHFFFAOYSA-N 0.000 claims description 8
- GEQNZVKIDIPGCO-UHFFFAOYSA-N 2,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C(OC)=C1 GEQNZVKIDIPGCO-UHFFFAOYSA-N 0.000 claims description 8
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 7
- WOYZXEVUWXQVNV-UHFFFAOYSA-N 4-phenoxyaniline Chemical compound C1=CC(N)=CC=C1OC1=CC=CC=C1 WOYZXEVUWXQVNV-UHFFFAOYSA-N 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 claims description 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 5
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 5
- ODSXJQYJADZFJX-UHFFFAOYSA-N 3,5-bis(trifluoromethyl)phenol Chemical compound OC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ODSXJQYJADZFJX-UHFFFAOYSA-N 0.000 claims description 4
- MNOJRWOWILAHAV-UHFFFAOYSA-N 3-bromophenol Chemical compound OC1=CC=CC(Br)=C1 MNOJRWOWILAHAV-UHFFFAOYSA-N 0.000 claims description 4
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims description 4
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 claims description 4
- 229960001867 guaiacol Drugs 0.000 claims description 4
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000006463 Talin Human genes 0.000 abstract description 42
- 108010083809 Talin Proteins 0.000 abstract description 42
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 22
- 230000002401 inhibitory effect Effects 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 14
- 230000003834 intracellular effect Effects 0.000 abstract description 3
- 239000011159 matrix material Substances 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 147
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 105
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 87
- 238000002360 preparation method Methods 0.000 description 79
- 239000007787 solid Substances 0.000 description 40
- 238000005160 1H NMR spectroscopy Methods 0.000 description 37
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 30
- 125000003118 aryl group Chemical group 0.000 description 28
- 125000001072 heteroaryl group Chemical group 0.000 description 26
- -1 hydrocarbon radical Chemical class 0.000 description 26
- 239000000243 solution Substances 0.000 description 26
- 125000000623 heterocyclic group Chemical group 0.000 description 24
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
- 210000001772 blood platelet Anatomy 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 17
- 125000005842 heteroatom Chemical group 0.000 description 16
- 229940012952 fibrinogen Drugs 0.000 description 15
- 108010049003 Fibrinogen Proteins 0.000 description 14
- 102000008946 Fibrinogen Human genes 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 14
- 239000011734 sodium Substances 0.000 description 12
- 238000004440 column chromatography Methods 0.000 description 11
- 108010044426 integrins Proteins 0.000 description 11
- 102000006495 integrins Human genes 0.000 description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 11
- SFMRLZQXQSMOJK-UHFFFAOYSA-N 2-(5-phenyltetrazol-2-yl)acetamide Chemical compound NC(=O)CN1N=NC(C=2C=CC=CC=2)=N1 SFMRLZQXQSMOJK-UHFFFAOYSA-N 0.000 description 10
- BDAQJKHBUZOXMH-UHFFFAOYSA-N 2-(5-phenyltetrazol-2-yl)acetyl isocyanate Chemical compound C1(=CC=CC=C1)C=1N=NN(N=1)CC(=O)N=C=O BDAQJKHBUZOXMH-UHFFFAOYSA-N 0.000 description 10
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- CMMLLICWVROPHY-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenoxy]-N-[(4-bromo-3-methoxyphenyl)carbamoyl]acetamide Chemical compound FC(C=1C=C(OCC(=O)NC(NC2=CC(=C(C=C2)Br)OC)=O)C=C(C=1)C(F)(F)F)(F)F CMMLLICWVROPHY-UHFFFAOYSA-N 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 210000005259 peripheral blood Anatomy 0.000 description 8
- 239000011886 peripheral blood Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- UIHGCVQRDONIEU-UHFFFAOYSA-N N-[(4-phenoxyphenyl)carbamoyl]-2-(5-phenyltetrazol-2-yl)acetamide Chemical compound O(C1=CC=CC=C1)C1=CC=C(C=C1)NC(=O)NC(CN1N=C(N=N1)C1=CC=CC=C1)=O UIHGCVQRDONIEU-UHFFFAOYSA-N 0.000 description 7
- 0 [1*]CC(=O)N([3*])C(=O)N([2*])[4*] Chemical compound [1*]CC(=O)N([3*])C(=O)N([2*])[4*] 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- WKJUGCJEECGMGJ-UHFFFAOYSA-N 2-(2,3-dimethylphenoxy)-N-[(2-fluorophenyl)carbamoyl]acetamide Chemical compound CC1=C(OCC(=O)NC(NC2=C(C=CC=C2)F)=O)C=CC=C1C WKJUGCJEECGMGJ-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 6
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- JZJQLECBQUFWHJ-UHFFFAOYSA-N n-[(2-fluorophenyl)carbamoyl]-2-(4-phenylmethoxyphenoxy)acetamide Chemical compound FC1=CC=CC=C1NC(=O)NC(=O)COC(C=C1)=CC=C1OCC1=CC=CC=C1 JZJQLECBQUFWHJ-UHFFFAOYSA-N 0.000 description 6
- VRRCUXCXNAPQIK-UHFFFAOYSA-N tert-butyl 4-[2-[(2-fluorophenyl)carbamoylamino]-2-oxoethyl]piperazine-1-carboxylate Chemical compound FC1=C(C=CC=C1)NC(NC(CN1CCN(CC1)C(=O)OC(C)(C)C)=O)=O VRRCUXCXNAPQIK-UHFFFAOYSA-N 0.000 description 6
- NGYRYUYXSJGNDY-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yloxy)-N-[(2-fluorophenyl)carbamoyl]acetamide Chemical compound O1COC2=C1C=CC(=C2)OCC(=O)NC(NC1=C(C=CC=C1)F)=O NGYRYUYXSJGNDY-UHFFFAOYSA-N 0.000 description 5
- AEFDQWHYGSRHBW-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yloxy)-N-[(4-phenoxyphenyl)carbamoyl]acetamide Chemical compound O1COC2=C1C=CC(=C2)OCC(=O)NC(NC1=CC=C(C=C1)OC1=CC=CC=C1)=O AEFDQWHYGSRHBW-UHFFFAOYSA-N 0.000 description 5
- SKDUYSMNUTZHEN-UHFFFAOYSA-N 2-(2-methoxyphenoxy)-N-[(4-phenoxyphenyl)carbamoyl]acetamide Chemical compound COC1=C(OCC(=O)NC(NC2=CC=C(C=C2)OC2=CC=CC=C2)=O)C=CC=C1 SKDUYSMNUTZHEN-UHFFFAOYSA-N 0.000 description 5
- BTPJVRPAAUVGBV-UHFFFAOYSA-N 2-(2-methoxyphenoxy)-N-[(4-phenylmethoxyphenyl)carbamoyl]acetamide Chemical compound C(C1=CC=CC=C1)OC1=CC=C(C=C1)NC(=O)NC(COC1=C(C=CC=C1)OC)=O BTPJVRPAAUVGBV-UHFFFAOYSA-N 0.000 description 5
- XVWYAPLAKCYDFZ-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenoxy]-N-[(3-fluoropyridin-2-yl)carbamoyl]acetamide Chemical compound FC(C=1C=C(OCC(=O)NC(NC2=NC=CC=C2F)=O)C=C(C=1)C(F)(F)F)(F)F XVWYAPLAKCYDFZ-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- RBDCKYTXGBPKTM-UHFFFAOYSA-N N-[(3-fluoropyridin-2-yl)carbamoyl]-2-(2-methoxyphenoxy)acetamide Chemical compound FC=1C(=NC=CC=1)NC(=O)NC(COC1=C(C=CC=C1)OC)=O RBDCKYTXGBPKTM-UHFFFAOYSA-N 0.000 description 5
- KNTLYQAEDRYUKN-UHFFFAOYSA-N N-[(4-bromo-3-methoxyphenyl)carbamoyl]-2-(2-methoxyphenoxy)acetamide Chemical compound BrC1=C(C=C(C=C1)NC(=O)NC(COC1=C(C=CC=C1)OC)=O)OC KNTLYQAEDRYUKN-UHFFFAOYSA-N 0.000 description 5
- JGDYWUUOOGBPMQ-UHFFFAOYSA-N N-[(4-bromo-3-methoxyphenyl)carbamoyl]-2-(5-phenyltetrazol-2-yl)acetamide Chemical compound BrC1=C(C=C(C=C1)NC(=O)NC(CN1N=C(N=N1)C1=CC=CC=C1)=O)OC JGDYWUUOOGBPMQ-UHFFFAOYSA-N 0.000 description 5
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 5
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 229940114079 arachidonic acid Drugs 0.000 description 5
- 235000021342 arachidonic acid Nutrition 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- NWCZRNIXKKGSPB-UHFFFAOYSA-N 2-(2-methoxyphenoxy)-N-[(4-methoxyphenyl)methylcarbamoyl]acetamide Chemical compound COC1=CC=C(CNC(=O)NC(COC2=C(C=CC=C2)OC)=O)C=C1 NWCZRNIXKKGSPB-UHFFFAOYSA-N 0.000 description 4
- AIAFHDPIXBTRAH-UHFFFAOYSA-N 2-(3-bromophenoxy)-N-[(2,4-dimethoxyphenyl)carbamoyl]acetamide Chemical compound BrC=1C=C(OCC(=O)NC(NC2=C(C=C(C=C2)OC)OC)=O)C=CC=1 AIAFHDPIXBTRAH-UHFFFAOYSA-N 0.000 description 4
- BRAOJFQDNZLTMZ-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenoxy]-N-[(2,4-dimethoxyphenyl)carbamoyl]acetamide Chemical compound FC(C=1C=C(OCC(=O)NC(NC2=C(C=C(C=C2)OC)OC)=O)C=C(C=1)C(F)(F)F)(F)F BRAOJFQDNZLTMZ-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- HVBNTHSUAAHRQP-UHFFFAOYSA-N N-[(2,4-dimethoxyphenyl)carbamoyl]-2-(2-methoxyphenoxy)acetamide Chemical compound COC1=C(C=CC(=C1)OC)NC(=O)NC(COC1=C(C=CC=C1)OC)=O HVBNTHSUAAHRQP-UHFFFAOYSA-N 0.000 description 4
- BIYXMKRYWHEESW-UHFFFAOYSA-N N-[(2,4-dimethoxyphenyl)carbamoyl]-2-(5-phenyltetrazol-2-yl)acetamide Chemical compound COC1=C(C=CC(=C1)OC)NC(=O)NC(CN1N=C(N=N1)C1=CC=CC=C1)=O BIYXMKRYWHEESW-UHFFFAOYSA-N 0.000 description 4
- YMEKYQYDDADZJU-UHFFFAOYSA-N N-[(4-bromo-3-methoxyphenyl)carbamoyl]-2-(3-bromophenoxy)acetamide Chemical compound BrC1=C(C=C(C=C1)NC(=O)NC(COC1=CC(=CC=C1)Br)=O)OC YMEKYQYDDADZJU-UHFFFAOYSA-N 0.000 description 4
- UDRBGAWJUYJIST-UHFFFAOYSA-N N-[(4-phenylmethoxyphenyl)carbamoyl]-2-(5-phenyltetrazol-2-yl)acetamide Chemical compound C(C1=CC=CC=C1)OC1=CC=C(C=C1)NC(=O)NC(CN1N=C(N=N1)C1=CC=CC=C1)=O UDRBGAWJUYJIST-UHFFFAOYSA-N 0.000 description 4
- NLSNXNWFAXIDRZ-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethylcarbamoyl]-2-(2-methoxyphenoxy)acetamide Chemical compound COc1ccccc1OCC(=O)NC(=O)NCCc1c[nH]c2ccccc12 NLSNXNWFAXIDRZ-UHFFFAOYSA-N 0.000 description 4
- BBHSFSTXGAGONJ-UHFFFAOYSA-N N-[2-(3a,7a-dihydro-1H-indol-3-yl)ethylcarbamoyl]-2-(5-phenyltetrazol-2-yl)acetamide Chemical compound N1C=C(C2C=CC=CC12)CCNC(=O)NC(CN1N=C(N=N1)C1=CC=CC=C1)=O BBHSFSTXGAGONJ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- XSXSLHZJSAPGAQ-UHFFFAOYSA-N n-[(2-fluorophenyl)carbamoyl]-2-morpholin-4-ylacetamide Chemical compound FC1=CC=CC=C1NC(=O)NC(=O)CN1CCOCC1 XSXSLHZJSAPGAQ-UHFFFAOYSA-N 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 125000001425 triazolyl group Chemical group 0.000 description 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 3
- GLNOJZKPFXQRMS-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yloxy)-N-[2-(1H-indol-3-yl)ethylcarbamoyl]acetamide Chemical compound N1C=C(C2=CC=CC=C12)CCNC(=O)NC(COC1=CC2=C(OCO2)C=C1)=O GLNOJZKPFXQRMS-UHFFFAOYSA-N 0.000 description 3
- WOHNKLXXAUSUCP-UHFFFAOYSA-N 2-(4-phenylmethoxyphenoxy)acetamide Chemical compound C1=CC(OCC(=O)N)=CC=C1OCC1=CC=CC=C1 WOHNKLXXAUSUCP-UHFFFAOYSA-N 0.000 description 3
- GTRMBKIQMVOQAA-UHFFFAOYSA-N 2-(4-phenylmethoxyphenoxy)acetyl isocyanate Chemical compound C(C1=CC=CC=C1)OC1=CC=C(OCC(=O)N=C=O)C=C1 GTRMBKIQMVOQAA-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- CVLSCSPNBJYATB-UHFFFAOYSA-N N-[(4-methoxyphenyl)methylcarbamoyl]-2-(5-phenyltetrazol-2-yl)acetamide Chemical compound COC1=CC=C(CNC(=O)NC(CN2N=C(N=N2)C2=CC=CC=C2)=O)C=C1 CVLSCSPNBJYATB-UHFFFAOYSA-N 0.000 description 3
- 150000007945 N-acyl ureas Chemical class 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- SQYKJFPNNJRBQQ-UHFFFAOYSA-N n-[(2-fluorophenyl)carbamoyl]-2-(2-methoxyphenoxy)acetamide Chemical compound COC1=CC=CC=C1OCC(=O)NC(=O)NC1=CC=CC=C1F SQYKJFPNNJRBQQ-UHFFFAOYSA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 2
- NOAOKSZQSUNEBL-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yloxy)-N-[(3-fluoropyridin-2-yl)carbamoyl]acetamide Chemical compound O1COC2=C1C=CC(=C2)OCC(=O)NC(NC1=NC=CC=C1F)=O NOAOKSZQSUNEBL-UHFFFAOYSA-N 0.000 description 2
- DJRVBQPSPHIEIO-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yloxy)-N-[(4-methoxyphenyl)methylcarbamoyl]acetamide Chemical compound O1COC2=C1C=CC(=C2)OCC(=O)NC(NCC1=CC=C(C=C1)OC)=O DJRVBQPSPHIEIO-UHFFFAOYSA-N 0.000 description 2
- PILFZJFTNQXMEH-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yloxy)-N-[(4-phenylmethoxyphenyl)carbamoyl]acetamide Chemical compound O1COC2=C1C=CC(=C2)OCC(=O)NC(NC1=CC=C(C=C1)OCC1=CC=CC=C1)=O PILFZJFTNQXMEH-UHFFFAOYSA-N 0.000 description 2
- TYZPTOLEXSSLKU-UHFFFAOYSA-N 2-(2,3-dimethylphenoxy)acetyl isocyanate Chemical compound CC1=CC=CC(OCC(=O)N=C=O)=C1C TYZPTOLEXSSLKU-UHFFFAOYSA-N 0.000 description 2
- SWSQFEAWQBOBAI-UHFFFAOYSA-N 2-(2-methoxyphenoxy)acetamide Chemical compound COC1=CC=CC=C1OCC(N)=O SWSQFEAWQBOBAI-UHFFFAOYSA-N 0.000 description 2
- JIGBVIFNXKYYMD-UHFFFAOYSA-N 2-(2-methoxyphenoxy)acetyl isocyanate Chemical compound COC1=CC=CC=C1OCC(=O)N=C=O JIGBVIFNXKYYMD-UHFFFAOYSA-N 0.000 description 2
- CIEWAUWCYCYVAJ-UHFFFAOYSA-N 2-(3,5-dimethylphenoxy)acetamide Chemical compound CC1=CC(C)=CC(OCC(N)=O)=C1 CIEWAUWCYCYVAJ-UHFFFAOYSA-N 0.000 description 2
- STBGWLWAHXTFMK-UHFFFAOYSA-N 2-(3-bromophenoxy)acetamide Chemical compound NC(=O)COC1=CC=CC(Br)=C1 STBGWLWAHXTFMK-UHFFFAOYSA-N 0.000 description 2
- ZNGHXOQBCQAUIM-UHFFFAOYSA-N 2-(3-bromophenoxy)acetyl isocyanate Chemical compound BrC1=CC=CC(OCC(=O)N=C=O)=C1 ZNGHXOQBCQAUIM-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- RBDLZQLBHGHRKZ-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenoxy]-N-[(2-fluorophenyl)carbamoyl]acetamide Chemical compound FC(C=1C=C(OCC(=O)NC(NC2=C(C=CC=C2)F)=O)C=C(C=1)C(F)(F)F)(F)F RBDLZQLBHGHRKZ-UHFFFAOYSA-N 0.000 description 2
- BTYXRFKWOAZXLD-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenoxy]-N-[(4-phenylmethoxyphenyl)carbamoyl]acetamide Chemical compound C(C1=CC=CC=C1)OC1=CC=C(C=C1)NC(=O)NC(COC1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)=O BTYXRFKWOAZXLD-UHFFFAOYSA-N 0.000 description 2
- ZSMFMJZDLBRCSK-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenoxy]-N-[2-(1H-indol-3-yl)ethylcarbamoyl]acetamide Chemical compound N1C=C(C2=CC=CC=C12)CCNC(=O)NC(COC1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)=O ZSMFMJZDLBRCSK-UHFFFAOYSA-N 0.000 description 2
- MKKVSRBOJJBGDN-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenoxy]acetamide Chemical compound NC(=O)COC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 MKKVSRBOJJBGDN-UHFFFAOYSA-N 0.000 description 2
- WDEYPSABQJYRGF-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenoxy]acetyl isocyanate Chemical compound FC(C=1C=C(OCC(=O)N=C=O)C=C(C=1)C(F)(F)F)(F)F WDEYPSABQJYRGF-UHFFFAOYSA-N 0.000 description 2
- PIHDYGGFNFGFRP-UHFFFAOYSA-N 2-chloro-n-[(2-fluorophenyl)carbamoyl]acetamide Chemical compound FC1=CC=CC=C1NC(=O)NC(=O)CCl PIHDYGGFNFGFRP-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102000015735 Beta-catenin Human genes 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000007466 Purinergic P2 Receptors Human genes 0.000 description 2
- 108010085249 Purinergic P2 Receptors Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 150000003869 acetamides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- PPTMJVGGFXPSMP-UHFFFAOYSA-N n-[(2-fluorophenyl)carbamoyl]-2-(5-phenyltetrazol-2-yl)acetamide Chemical compound FC1=CC=CC=C1NC(=O)NC(=O)CN1N=C(C=2C=CC=CC=2)N=N1 PPTMJVGGFXPSMP-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000003087 receptor blocking agent Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- KZAFZLFFVFZDPM-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yloxy)-N-[(2,4-dimethoxyphenyl)carbamoyl]acetamide Chemical compound O1COC2=C1C=CC(=C2)OCC(=O)NC(NC1=C(C=C(C=C1)OC)OC)=O KZAFZLFFVFZDPM-UHFFFAOYSA-N 0.000 description 1
- JOOYQCIQARGKSR-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yloxy)-N-[(4-bromo-3-methoxyphenyl)carbamoyl]acetamide Chemical compound O1COC2=C1C=CC(=C2)OCC(=O)NC(NC1=CC(=C(C=C1)Br)OC)=O JOOYQCIQARGKSR-UHFFFAOYSA-N 0.000 description 1
- LDENUWVDTLYIAD-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yloxy)acetamide Chemical compound NC(=O)COC1=CC=C2OCOC2=C1 LDENUWVDTLYIAD-UHFFFAOYSA-N 0.000 description 1
- OXHBNYHEAMUDOI-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yloxy)acetyl isocyanate Chemical compound O=C=NC(=O)COC1=CC=C2OCOC2=C1 OXHBNYHEAMUDOI-UHFFFAOYSA-N 0.000 description 1
- LJQBJASXPUGHKJ-UHFFFAOYSA-N 2-(2,3-dimethylphenoxy)acetamide Chemical compound CC1=CC=CC(OCC(N)=O)=C1C LJQBJASXPUGHKJ-UHFFFAOYSA-N 0.000 description 1
- HJKFZCATMNMNRT-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenoxy]-N-[(4-methoxyphenyl)methylcarbamoyl]acetamide Chemical compound FC(C=1C=C(OCC(=O)NC(NCC2=CC=C(C=C2)OC)=O)C=C(C=1)C(F)(F)F)(F)F HJKFZCATMNMNRT-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- XBHQOMRKOUANQQ-UHFFFAOYSA-N 2-ethoxypropanoic acid Chemical class CCOC(C)C(O)=O XBHQOMRKOUANQQ-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- MARUHZGHZWCEQU-UHFFFAOYSA-N 5-phenyl-2h-tetrazole Chemical compound C1=CC=CC=C1C1=NNN=N1 MARUHZGHZWCEQU-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- AHBQYMXUVLWRJM-UHFFFAOYSA-N COc1cc(CC(=O)CC(=O)Cn2nnc(-c3ccccc3)n2)ccc1Br Chemical compound COc1cc(CC(=O)CC(=O)Cn2nnc(-c3ccccc3)n2)ccc1Br AHBQYMXUVLWRJM-UHFFFAOYSA-N 0.000 description 1
- GFJVIXUSWWSONO-UHFFFAOYSA-N COc1cc(CO)ccc1CC(=O)CC(=O)Cn1nnc(-c2ccccc2)n1 Chemical compound COc1cc(CO)ccc1CC(=O)CC(=O)Cn1nnc(-c2ccccc2)n1 GFJVIXUSWWSONO-UHFFFAOYSA-N 0.000 description 1
- MHXPHNPDCOSSCB-UHFFFAOYSA-N COc1cc(CO)ccc1NC(=O)NC(=O)COc1cc(C(F)(F)F)cc(C(F)(F)F)c1 Chemical compound COc1cc(CO)ccc1NC(=O)NC(=O)COc1cc(C(F)(F)F)cc(C(F)(F)F)c1 MHXPHNPDCOSSCB-UHFFFAOYSA-N 0.000 description 1
- DUMPNWWAMQZHDG-UHFFFAOYSA-N COc1cc(CO)ccc1NC(=O)NC(=O)COc1ccc2c(c1)OCO2 Chemical compound COc1cc(CO)ccc1NC(=O)NC(=O)COc1ccc2c(c1)OCO2 DUMPNWWAMQZHDG-UHFFFAOYSA-N 0.000 description 1
- LMBWHALCYYUSDZ-UHFFFAOYSA-N COc1cc(CO)ccc1NC(=O)NC(=O)COc1cccc(Br)c1 Chemical compound COc1cc(CO)ccc1NC(=O)NC(=O)COc1cccc(Br)c1 LMBWHALCYYUSDZ-UHFFFAOYSA-N 0.000 description 1
- QVTMBCODEWGZRI-UHFFFAOYSA-N COc1cc(CO)ccc1NC(=O)NC(=O)COc1ccccc1OC Chemical compound COc1cc(CO)ccc1NC(=O)NC(=O)COc1ccccc1OC QVTMBCODEWGZRI-UHFFFAOYSA-N 0.000 description 1
- QYYQHSDSXUWHDT-UHFFFAOYSA-N COc1ccccc1OCC(=O)NC(=O)NCc1ccc(CO)cc1 Chemical compound COc1ccccc1OCC(=O)NC(=O)NCc1ccc(CO)cc1 QYYQHSDSXUWHDT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- MHBMHVOONIHTIU-UHFFFAOYSA-N Cc1cc(NC(=O)NC(=O)COc2cccc(Br)c2)ccc1Br Chemical compound Cc1cc(NC(=O)NC(=O)COc2cccc(Br)c2)ccc1Br MHBMHVOONIHTIU-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- HMIRJXCNAZPKCI-UHFFFAOYSA-N O=C(CC(=O)Cn1nnc(-c2ccccc2)n1)Cc1ccc(OCc2ccccc2)cc1 Chemical compound O=C(CC(=O)Cn1nnc(-c2ccccc2)n1)Cc1ccc(OCc2ccccc2)cc1 HMIRJXCNAZPKCI-UHFFFAOYSA-N 0.000 description 1
- ONUCMPWRWOFUOL-UHFFFAOYSA-N O=C(CC(=O)Cn1nnc(-c2ccccc2)n1)Cc1ccc(Oc2ccccc2)cc1 Chemical compound O=C(CC(=O)Cn1nnc(-c2ccccc2)n1)Cc1ccc(Oc2ccccc2)cc1 ONUCMPWRWOFUOL-UHFFFAOYSA-N 0.000 description 1
- SNPYYLYFRGUARC-UHFFFAOYSA-N O=C(CC(=O)Cn1nnc(-c2ccccc2)n1)Cc1ccccc1F Chemical compound O=C(CC(=O)Cn1nnc(-c2ccccc2)n1)Cc1ccccc1F SNPYYLYFRGUARC-UHFFFAOYSA-N 0.000 description 1
- VQNFTZORQAUHLW-UHFFFAOYSA-N O=C(CCCC1=CNC2C=CC=CC12)CC(=O)Cn1nnc(-c2ccccc2)n1 Chemical compound O=C(CCCC1=CNC2C=CC=CC12)CC(=O)Cn1nnc(-c2ccccc2)n1 VQNFTZORQAUHLW-UHFFFAOYSA-N 0.000 description 1
- NHWIPLGIPSXNPA-UHFFFAOYSA-N O=C(CCc1ccc(CO)cc1)CC(=O)Cn1nnc(-c2ccccc2)n1 Chemical compound O=C(CCc1ccc(CO)cc1)CC(=O)Cn1nnc(-c2ccccc2)n1 NHWIPLGIPSXNPA-UHFFFAOYSA-N 0.000 description 1
- LRVNKBPOMQWYSN-UHFFFAOYSA-N O=C(COc1cc(C(F)(F)F)cc(C(F)(F)F)c1)NC(=O)NCc1ccc(CO)cc1 Chemical compound O=C(COc1cc(C(F)(F)F)cc(C(F)(F)F)c1)NC(=O)NCc1ccc(CO)cc1 LRVNKBPOMQWYSN-UHFFFAOYSA-N 0.000 description 1
- HJKTVRMHQJCHBU-UHFFFAOYSA-N O=C(COc1cc(C(F)(F)F)cc(C(F)(F)F)c1)NC(=O)Nc1ccc(Oc2ccccc2)cc1 Chemical compound O=C(COc1cc(C(F)(F)F)cc(C(F)(F)F)c1)NC(=O)Nc1ccc(Oc2ccccc2)cc1 HJKTVRMHQJCHBU-UHFFFAOYSA-N 0.000 description 1
- NCSJZQIRHMASKI-UHFFFAOYSA-N O=C(COc1ccc2c(c1)OCO2)NC(=O)NCc1ccc(CO)cc1 Chemical compound O=C(COc1ccc2c(c1)OCO2)NC(=O)NCc1ccc(CO)cc1 NCSJZQIRHMASKI-UHFFFAOYSA-N 0.000 description 1
- DUIBFTCBFCRBRB-UHFFFAOYSA-N O=C(COc1ccc2c(c1)OCO2)NC(=O)Nc1ccc(Br)c(CO)c1 Chemical compound O=C(COc1ccc2c(c1)OCO2)NC(=O)Nc1ccc(Br)c(CO)c1 DUIBFTCBFCRBRB-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108010022425 Platelet Glycoprotein GPIIb-IIIa Complex Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000003970 Vinculin Human genes 0.000 description 1
- 108090000384 Vinculin Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000005275 alkylenearyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004662 cellular morphological change Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005050 dihydrooxazolyl group Chemical group O1C(NC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000005961 oxazepanyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000012910 preclinical development Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
- C07C275/48—Y being a hydrogen or a carbon atom
- C07C275/50—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to a novel N-acylurea derivative and the use thereof for the prevention or treatment of cardiovascular disease, and more particularly to a novel N-acylurea derivative, a pharmaceutical composition for preventing or treating cardiovascular disease, which contains the N-acylurea derivative as an active ingredient, and a method of preparing the N-acylurea derivative.
- Talin molecule which is one of the cytoskeletal components is a cytoplasmic protein. It is known that the talin molecule links integrin to the cytoskeleton directly or indirectly by interaction with vinculin and ⁇ -actinin (Alan D. Michelson, Platelets, Second Edition, 2006).
- the present inventors have made extensive efforts to develop a substance capable of treating and preventing talin-related diseases by reducing talin expression, and as a result, have synthesized novel N-acylurea derivatives and have found that the novel N-acylurea derivatives exhibit the effect of inhibiting platelet aggregation by inhibiting the activity of talin and effectively regulating cellular morphological changes and growth, thereby completing the present invention.
- Another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of cardiovascular disease, comprising the N-acyl urea derivative or the pharmaceutically acceptable salt thereof as an active ingredient.
- Still another object of the present invention is to provide a method of preparing the N-acylurea derivative or the pharmaceutically acceptable salt thereof.
- the present invention provides a novel N-acylurea derivative which is a compound represented by Formula 1 below, or a pharmaceutically acceptable salt thereof:
- R 1 is hydrogen, halogen, hydroxy, C 1-6 alkyl, C 1-6 haloaklyl, C 6-12 aryl, C 1-12 heteroaryl, C 1-12 heterocyclyl, C 1-6 alkyl linked by heteroatom, or a C 6-12 aryl linked by heteroatom, C 1-12 heteroaryl or C 1-12 heterocyclyl, wherein the aryl, heteroaryl or heterocyclyl may be unsubstituted or substituted, and the heteroatom is selected from N, O and S;
- R 2 is hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 6-12 aryl, C 1-12 heteroaryl, C 1-12 heterocyclyl, C 2-20 alkylene-C 6-12 aryl, C 2-20 alkylene-C 1-12 heteroaryl, or C 2-20 alkylene-C 1-12 heterocyclyl, wherein the aryl, heteroaryl or heterocyclyl may be unsubstituted or substituted, and the heteroatom is selected from N, O and S; and
- R 3 and R 4 are each independently hydrogen, C 1-6 alkyl or C 1-6 haloalkyl.
- the present invention also provides a pharmaceutical composition for the prevention or treatment of cardiovascular disease, which contains the novel N-acylurea derivative or the pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention also provides a method of preparing the novel N-acyl urea derivative represented by above Formula 1, or the pharmaceutically acceptable salt thereof, comprising: (a) obtaining acetamide by mixing and reacting 2-chloroacetamide, N,N-dimethylformamide, potassium carbonate and a nucleophilic reagent in a reactor, terminating a reaction by addition of water, followed by concentrating; (b) obtaining acetyl isocyanate by adding oxalyl chloride to the obtained acetamide, adding dichloroethane and heating and stirring, followed by concentrating; and (c) obtaining a compound by adding methylene chloride to the obtained acetyl isocyanate, adding and reacting a nucleophilic reagent, followed by concentrating.
- the present invention also provides a method of preparing the N-acyl urea derivative of above Formula 1, or the pharmaceutically acceptable salt thereof, comprising: (a) obtaining 2-chloroacetyl isocyanate by mixing 2-chloroacetamide and oxalyl chloride in a reactor, adding dichloroethane and heating and stirring, followed by concentrating; (b) obtaining carbamoyl 2-chloroacetamide by adding methylene chloride to the obtained 2-chloroacetyl isocyanate, and then adding a nucleophilic reagent and reacting, followed by concentrating; and (c) obtaining N-acylurea derivative by adding methanol to the obtained carbamoyl 2-chloroacetamide, adding and reacting a nucleophilic reagent while stirring, extracting an N-acylurea derivative using an organic solvent.
- FIG. 1 shows the results of Western blot analysis performed to confirm the effect of a compound of the present invention (a compound of Preparation Example 30 or a compound of Preparation Example 31) on the inhibition of ⁇ -catenin expression in HEK293 cells in which the Wnt/ ⁇ -catenin pathway was activated by treatment with Wnt-3a CM.
- FIG. 1 is a schematic view showing an experimental method for high-throughput screening of thrombosis inhibitory candidates in Example 38 of the present invention.
- FIG. 2 shows the results of screening thrombosis inhibitory candidates according to Example 38 of the present invention.
- Cells expressing platelet integrin ⁇ IIb ⁇ 3 were incubated with 0.2 mM of candidates, and the binding between the cells and fibrinogen was verified according to the experimental method shown in FIG. 1 .
- 0% is a negative control and represents the degree to which cells adhere to a surface coated with bovine serum albumin (BSA) instead of fibrinogen
- BSA bovine serum albumin
- 100% is a positive control and represents the degree to which cells adhere to fibrinogen in the absence of any candidate.
- the ability of candidates to inhibit fibrinogen binding was normalized to 100%, and the mean and standard error of three experiments are graphically shown.
- FIG. 3 shows the results of testing the concentration-dependent inhibitory activity of effective representative thrombosis inhibitory candidates in Example 38 of the present invention.
- FIG. 4 shows the results of measuring the binding affinity of talin antagonist candidates for talin protein by surface plasmon resonance spectroscopy in Example 39 of the present invention.
- FIG. 5 shows the results of analyzing the platelet aggregation inhibitory effects of KCH-1513 and KCH-1521 in Example 40 of the present invention.
- FIG. 6 depicts graphs showing the results obtained by treating human peripheral blood with platelet aggregation agonists (TRAP, ADP and arachidonic acid), and then treating the blood again with compounds of the present invention, and comparing and quantifying the inhibition of platelet aggregation, in Example 41 of the present invention in order to compare the platelet aggregation inhibitory activities of various compounds in human peripheral blood.
- platelet aggregation agonists TRAP, ADP and arachidonic acid
- FIG. 7 schematically shows a mechanism by which the novel N-acylurea derivative of the present invention acts.
- FIG. 8 depicts graphs showing the results obtained by treating human peripheral blood (which has been administered with conventional platelet inhibitors) with platelet aggregation agonists (TRAP, ADP and arachidonic acid), and then treating the blood again with compounds of the present invention, and comparing and quantifying the inhibition of platelet aggregation, in Example 42 of the present invention in order to compare the platelet aggregation inhibitory activities of various compounds in human peripheral blood.
- platelet aggregation agonists TRAP, ADP and arachidonic acid
- the present invention is directed to an N-acylurea derivative represented by Formula 1 below or a pharmaceutically acceptable salt thereof:
- R 1 is hydrogen, halogen, hydroxy, C 1-6 alkyl, C 1-6 haloaklyl, C 6-12 aryl, C 1-12 heteroaryl, C 1-12 heterocyclyl, C 1-6 alkyl linked by heteroatom, or a C 6-12 aryl linked by heteroatom, C 1-12 heteroaryl or C 1-12 heterocyclyl, wherein the aryl, heteroaryl or heterocyclyl may be unsubstituted or substituted, and the heteroatom is selected from N, O and S;
- R 2 is hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 6-12 aryl, C 1-12 heteroaryl, C 1-12 heterocyclyl, C 2-20 alkylene-C 6-12 aryl, C 2-20 alkylene-C 1-12 heteroaryl, or C 2-20 alkylene-C 1-12 heterocyclyl, wherein the aryl, heteroaryl or heterocyclyl may be unsubstituted or substituted, and the heteroatom is selected from N, O and S; and R 3 and R 4 are each independently hydrogen, C 1-6 alkyl or C 1-6 haloalkyl.
- C 1-6 alkyl refers to a monovalent linear or branched saturated hydrocarbon radical (or moiety), consisting solely of carbon and hydrogen atoms, having one to six carbon atoms.
- alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, n-hexyl and the like.
- Examples of “branched alkyl” include isopropyl, isobutyl, tert-butyl and the like.
- C 1-6 haloalkyl means a C 1-6 alkyl as defined herein wherein at least one of the hydrogen atoms of the alkyl group has been substituted by the same or different halogen atoms.
- haloalkyl include —CH 2 Cl, —CH 2 CF 3 , —CH 2 CCl 3 , perfluoroalkyl (e.g., —CF 3 ) and the like.
- C 2-20 alkylene means a linear saturated divalent hydrocarbon radical having 2 to 20 carbon atoms, or a branched saturated divalent hydrocarbon radical having 3 to 20 carbon atoms, e.g., methylene, ethylene, 2,2-dimethylethylene, propylene, 2-methylpropylene, butylene, pentylene, and the like.
- C 1-6 alkoxy means to a moiety of the formula —O—C 1-6 alkyl.
- Examples of C 1-6 alkoxy moieties include, but are not limited to, methoxy, ethoxy, isopropoxy, tert-butoxy, and the like.
- C 6-12 aryl means a monovalent cyclic aromatic hydrocarbon radical having 6 to 12 carbon atoms and consisting of a mono-, bi- or tricyclic aromatic ring.
- the aryl group may be substituted or unsubstituted as defined herein.
- the aryl group may be a substituted or unsubstituted phenyl group, or a substituted or unsubstituted naphthyl group.
- the aryl group is a substituted or unsubstituted phenyl group.
- C 1-12 heteroaryl means a monocyclic, bicyclic or tricyclic radical of 5 to 12, specifically 6 to 10 ring atoms having at least one aromatic ring containing one, two, or three ring heteroatoms selected from N, O, and S, the remaining ring atoms being C, with the understanding that the attachment point of the heteroaryl radical will be on an aromatic ring.
- the heteroaryl ring may be a 5- or 6-membered monocyclic ring containing one, two, or three ring heteroatoms selected from N, O, and S, the remaining ring atoms being C.
- the heteroaryl ring may be substituted or unsubstituted as defined herein.
- heteroaryl moieties include, but are not limited to, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, thienyl (i.e., thiopenyl), furanyl, pyranyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolinyl, iso quinolinyl, benzofuryl (i.e., benzofuranyl), benzothiophenyl, benzothiopyranyl, benzimidazolyl, benzoxazolyl, benzooxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzopyranyl, indolyl, isoindolyl, triazolyl,
- heteroaryl moieties examples include pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, indolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, which may be each substituted or unsubstituted.
- the heteroaryl moiety is triazolyl, tetrazolyl, pyridinyl, or indolyl, which may be each substituted or unsubstituted as defined herein.
- C 1-12 heterocyclyl means a 4- to 9-membered saturated or partially unsaturated carbocyclic ring containing, in addition to carbon atoms, one, two, or three ring heteroatoms selected from N, O and S.
- the two rings share two common ring atoms. That is, the bridge that separates the two rings is a single bond or a 1- or 2-membered chain.
- the heterocyclyl ring may be substituted or unsubstituted as defined herein.
- heterocyclyl moieties include, but are not limited to, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyranyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholin-4-yl, azepanyl, diazepanyl, homopiperazinyl, oxazepanyl, dihydroindolyl, dihydrofuryl, dihydroimidazolinyl, dihydrooxazolyl, tetrahydropyridinyl, dihydropyranyl, or benzodioxolyl.
- heterocyclyl is piperazinyl, morpholinyl, benzodioxolyl, or dihydroindolyl, which may be each substituted or unsubstituted as defined herein.
- aryl, heteroaryl or heterocyclyl linked by heteroatom refers to aryl, heteroaryl or heterocyclyl linked by the heteroatom 0, S or Se.
- the heteroatom is O or S.
- R 1 is hydrogen, halogen, hydroxy, C 1-6 alkyl, C 1-6 haloaklyl, C 6-12 aryl, C 1-12 heteroaryl, C 1-12 heterocyclyl, C 1-6 alkyl linked by heteroatom, or a C 6-12 aryl linked by heteroatom, C 1-12 heteroaryl or C 1-12 heterocyclyl, wherein the aryl, heteroaryl or heterocyclyl may be unsubstituted or substituted with one to three substituents selected from the group consisting of halogen, hydroxy, C 1-6 alkyl, C 1-6 haloaklyl, C 1-6 alkoxy, C 1-6 haloalkoxy, —C 1-6 alkoxy-C 1-6 alkyl, C 1-6 alkoxycarbonyl, —O-aryl, —O-heteroaryl, and —O—C 2-20 alkylene-aryl.
- R 1 is tetrazolyl, piperazinyl, morpholinyl, phenyl linked by O, or benzodioxolyl linked by O, wherein the tetrazolyl, piperazinyl, morpholinyl or benzodioxolyl may be unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of halogen, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 alkoxycarbonyl, phenoxy, and —O—C 2-20 alkylene-phenyl.
- the tetrazolyl, piperazinyl, morpholinyl or benzodioxolyl may be substituted with 1 to 3 substituents selected from the group consisting of F, Br, CF 3 , methoxy, t-butoxycarbonyl, phenoxy, and —O—CH 2 -phenyl.
- R 2 is hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 6-12 aryl, C 1-12 heteroaryl, C 1-12 heterocyclyl, C 2-20 alkylene-C 6-12 aryl, C 2-20 alkylene-C 1-12 heteroaryl, or C 2-20 alkylene-C 1-12 heterocyclyl, wherein the aryl, heteroaryl or heterocyclyl may be unsubstituted or substituted with one to three substituents selected from the group consisting of halogen, hydroxy, C 1-6 alkyl, C 1-6 haloaklyl, C 1-6 alkoxy, C 1-6 haloalkoxy, —C 1-6 alkoxy-C 1-6 alkyl, C 1-6 alkoxycarbonyl, —O-aryl, —O-heteroaryl, and —O—C 2-20 alkylene-C 6-12 aryl.
- R 2 is phenyl, pyridinyl, C 2-20 alkylene-phenyl, C 2-20 alkylene-indolyl, or C 2-20 alkylene-dihydroindolyl, wherein the phenyl, pyridinyl, indolyl, or dihydroindolyl may be unsubstituted or substituted with one to three substituents selected from the group consisting of halogen, hydroxy, C 1-6 alkyl, C 1-6 haloaklyl, C 1-6 alkoxy, C 1-6 haloalkoxy, —C 1-6 alkoxy-C 1-6 alkyl, —O-phenyl, and ⁇ 0-C 2 -20 alkylene-phenyl.
- R 2 is phenyl, pyridinyl, C 2-6 alkylene-phenyl, C 2-6 alkylene-indolyl, or C 2-6 alkylene-dihydroindolyl, wherein the phenyl, pyridinyl, indolyl, or dihydroindolyl may be unsubstituted or substituted with one to three substituents selected from the group consisting of halogen, C 1-6 alkoxy, phenoxy, and ⁇ O—C 2-6 alkylene-phenyl.
- the phenyl, pyridinyl, indolyl, or dihydroindolyl may be substituted with 1 to 3 substituents selected from the group consisting of F, Br, methoxy, phenoxy, and —O—CH 2 -phenyl.
- R 3 and R 4 are each independently hydrogen, C 1-6 alkyl, or C 1-6 haloalkyl.
- R 3 and R 4 are each hydrogen.
- the N-acylurea derivative of Formula 1 above according to the present invention comprises a pharmaceutically acceptable salt thereof, and a hydrate and a solvate prepared therefrom.
- the compound represented by Formula 1 designated is intended to embrace a pharmaceutically acceptable salt thereof.
- the pharmaceutically acceptable salt can be prepared by a salt preparation method that is commonly used in the art.
- the term “pharmaceutically acceptable salt” refers to a salt prepared from a pharmaceutically acceptable non-toxic base or acid including an inorganic or organic base and an inorganic or organic acid.
- the salt derived from an inorganic base is preferably aluminum, ammonium, calcium, magnesium, potassium or sodium salt.
- a solid salt may have one or more crystal structures, or otherwise may be in the form of a hydrate.
- Examples of the salt derived from a pharmaceutically acceptable non-toxic organic base include a primary, secondary or tertiary amine, a substituted amine such as a naturally-occurring substituted amine, a cyclic amine, or a basic ion exchange resin such as arginine, betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resin, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, or the like.
- a salt thereof may be prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids.
- the acid include acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucic acid, nitric acid, pamoic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, p-toluene sulfonic acid, and the like.
- the pharmaceutically acceptable salt may preferably be acetic, citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, fumaric, or tartaric acid.
- a hydrate of a compound represented by Formula 1 of the present invention or a pharmaceutically acceptable salt thereof is intended to embrace a stoichiometric or non-stoichiometric amount of water bound thereto by non-covalent intermolecular forces.
- the hydrate may contain one or more equivalents of water, typically 1 to 5 equivalents of water.
- the hydrate may be prepared by crystallization of the compound represented by Formula 1 of the present invention or a pharmaceutically acceptable salt thereof in water or water-containing solvent.
- a solvate of a compound represented by Formula 1 of the present invention or a pharmaceutically acceptable salt thereof is intended to embrace a stoichiometric or non-stoichiometric amount of a solvent bound thereto by non-covalent intermolecular forces.
- Preferred solvents are volatile, non-toxic, and suitable for administration to humans.
- the present invention is directed to a pharmaceutical composition for the prevention or treatment of cardiovascular disease, which contains a novel N-acylurea derivative or a pharmaceutically acceptable salt thereof as an active ingredient.
- the cardiovascular disease of the present invention includes, but is not limited to, hypertension, ischemic heart disease, coronary artery disease, angina pectoris, myocardial infarction, arteriosclerosis, cerebrovascular disease, arrhythmia and the like.
- Examples 44 and 45 were performed in order to verify the talin activity regulation induced by the compound of Formula 1 according to the present invention, and as a result, it was shown that the N-acylurea derivative inhibited the activity of talin by binding directly to the talin protein, and thus showed excellent antiplatelet effects. Accordingly, a pharmaceutical composition containing the compound of Formula 1 or the pharmaceutically acceptable salt thereof according to the present invention can be advantageously used to prevent or treat thrombotic cardiovascular disease by regulating the talin network.
- FIG. 7 shows the antiplatelet mechanism of the novel N-acylurea derivative of the present invention.
- a talin molecule binds to a GPIIb/IIIa protein, which is present in an inactive state, by a thrombotic signal, thereby causing a morphological change in the GPIIb/IIIa protein and activating the GPIIb/IIIa protein ( FIG. 7A ).
- the novel N-acylurea derivative of the present invention binds to the talin molecule, thereby inhibiting the talin molecule from binding directly to the GPIIb/IIIa protein. This maintains the GPIIb/IIIa protein in an inactive state ( FIG. 7B ).
- the present invention is directed to a method of inhibiting the binding of a talin molecule to a GPIIb/IIIa protein by binding the compound of Formula 1 to the talin molecule.
- the pharmaceutical composition of the present invention may further comprise a suitable carrier, excipient or diluent that is generally used in the preparation of drugs.
- the pharmaceutical composition according to the present invention can be formulated according to a conventional method.
- it may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, agents for oral and external applications, suppositories, or sterile injection solutions.
- Carriers, excipients and diluents that can be contained in the composition according to the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
- a pharmaceutical composition according to the present invention is formulated using diluents or excipients, such as fillers, extenders, binders, wetting agents, disintegrants or surfactants, which are commonly used.
- Solid Formulations for oral administration include tablets, pills, powders, granules, capsules, etc. Such solid Formulations are prepared by mixing the composition of present invention with at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc.
- excipient such as starch, calcium carbonate, sucrose, lactose, gelatin, etc.
- lubricants such as magnesium stearate, talc, etc. may also be added.
- Liquid Formulations for oral administration such as suspensions, internal solutions, emulsions, syrups, etc.
- Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized agents, suppositories, etc.
- Non-aqueous solvents and suspensions may be prepared using propylene glycol, polyethylene glycol, vegetable oils such as olive oil, or injectable esters such as ethyloleate.
- As a base for suppositories Witepsol, Macrogol, Tween 61, cacao fat, laurin fat, glycerogelatin, etc. may be used.
- composition of the present invention may be administered orally or parenterally. Any parenteral administration method can be used, and systemic or topical administration can be carried out, but the systemic administration is more preferable and the intravenous administration is most preferable.
- composition according to the present invention is administered in a pharmaceutically effective amount.
- pharmaceutically effective amount refers to an amount sufficient to treat the disease at a reasonable benefit/risk ratio applicable for any medical treatment.
- the effective dosage level of the composition may be determined depending on the type of a patient's disease, the severity of disease, the activity of the drug, sensitivity to the drug, the time of administration, the route of administration and the excretion rate, the duration of treatment, factors including drugs used in combination with the composition, and other factors known in the medical field.
- the pharmaceutical composition of the present invention may be administered individually or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents.
- the composition can be administered in a single or multiple dosage form. It is important to administer the composition in the minimum amount that can exhibit the maximum effect without causing side effects, in view of all the above-described factors, and this amount can be easily determined by a person skilled in the art.
- the effective amount of the compound according to the present invention may vary depending on the patient's age, sex and body weight, and the compound of the present invention may generally be administered at a daily or two-day dose of from 0.1 to 100 mg, preferably from 0.5 to 10 mg per body weight 1 kg, or may be administered one time to three times per day.
- the dosage may be increased or decreased depending on the route of administration, the severity of the obesity, sex, body weight, age, and thus it is not intended to limit the scope of the present invention in any way.
- the present invention is directed to a method of preparing the compound of Formula 1 above, comprising the steps of: (a) mixing and reacting 2-chloroacetamide, N,N-dimethylformamide, potassium carbonate and a nucleophilic reagent in a reactor, terminating the reaction by addition of water, followed by concentration to obtain acetamide; (b) adding oxalyl chloride to the obtained acetamide, replacing the inside of a reactor with argon, and then introducing dichloroethane into the reactor, and heating and stirring, followed by concentration to obtain acetyl isocyanate; and (c) adding methylene chloride to the obtained acetyl isocyanate, adding and reacting a nucleophilic reagent, and terminating the reaction by addition of water, followed by concentration to obtain an N-acylurea derivative.
- the obtaining of acetamide in step (a) may comprise dilution with ethyl acetate, washing with water, drying an organic layer with MgSO 4 , filtration, concentration under reduced pressure, and subjecting the concentrated compound to column chromatography with ethyl acetate/n-hexane.
- the heating in step (a) may be performed at 60-100° C., preferably 75-90° C.
- the obtaining of the N-acylurea derivative in step (c) may comprise diluting the residue, concentrated under reduced pressure, with a suitable solvent, washing with water, collecting an organic layer, drying the organic layer with MgSO 4 , filtration, concentration under reduced pressure, and subjecting the concentrated compound to column chromatography.
- the present invention is directed to a method of preparing the compound of Formula 1 above, comprising the steps of: (a) mixing 2-chloroacetamide with oxalyl chloride in a reactor, replacing the inside of the reactor with argon, introducing dichloroethane into reactor, and heating and stirring, followed by concentration to obtain 2-chloroacetyl isocyanate; (b) adding methylene chloride to the obtained 2-chloroacetyl isocyanate, adding and reacting a nucleophilic reagent, and terminating the reaction by addition of water, followed by concentration to obtain carbamoyl 2-chloroacetamide; and (c) adding methanol to the obtained carbamoyl 2-chloroacetamide, adding and reacting a nucleophilic reagent while stirring, terminating the reaction by addition of water, extracting an N-acylurea derivative with an organic solvent, and then recovering the N-acylurea derivative.
- the nucleophilic reagent may be selected from the group consisting of 4-bromo-3-methoxyanilin, 4-methoxybenzylamine, tryptamine, 2,4-dimethoxyaniline, 4-(benzyloxy)aniline, 2-fluoroaniline, Sesamol, 3-fluoropyridin-2-amine, 4-methoxyphenyl)methanamine, 4-(benzyloxy)aniline HCl, 2-Methoxyphenol, 4-phenoxyaniline, 3,5-bis(trifluoromethyl)phenol, 3-bromophenol, 4-bromo-3-methoxyaniline, 2,3-dimethylphenol), and 4-(benzyloxy)phenol.
- the heating in step (a) may be performed at 60-100° C., preferably 75-90° C.
- the obtaining of the 2-chloroacetyl isocyanate in step (b) may comprise diluting the residue, concentrated under reduced pressure, with a solvent, drying an organic layer with MgSO 4 , filtration, concentration under reduced pressure, and then subjecting the concentrated compound to column chromatography.
- the obtaining of the N-acylurea derivative in step (c) may comprise extracting the residue, concentrated under reduced pressure, with ethyl acetate, drying an organic layer with MgSO 4 , filtration, concentration under reduced pressure, and then subjecting the concentrated compound to column chromatography.
- 2-chloroacetamide (1) was placed in a reactor, and N,N-dimethylformamide was added thereto.
- Potassium carbonate (3 equivalents) and a nucleophilic reagent (1 equivalent) were added, followed by stirring overnight at a suitable temperature.
- the reaction was terminated by adding H 2 O to the reaction solution, followed by concentration under reduced pressure.
- the residue was diluted with ethyl acetate and washed with water, and the organic layer was dried with MgSO 4 , filtered, and then concentrated under reduced pressure. The concentrated compound was subjected to column chromatography with ethyl acetate/n-hexane to obtain the desired compound (3).
- the acetyl isocyanate obtained in step 2 above was placed in a reactor, and methylene chloride was added thereto, followed by addition of a nucleophilic reagent (5) (1 equivalent).
- the reaction solution was stirred overnight at room temperature.
- the reaction was terminated by adding H 2 O to the reaction solution, followed by concentration under reduced pressure.
- the residue was diluted with a suitable solvent and washed with water, and then the organic layer was collected.
- the organic layer was dried with MgSO 4 , filtered, and then concentrated under reduced pressure. The concentrated compound was subjected to column chromatography to obtain the desired compound (6).
- Step 1 Preparation of 2-Chloroacetyl Isocyanate (7)
- Commercially available 2-chloroacetamide (1) and oxalyl chloride (1.5 equivalents) were placed in a reactor, and the inside of the reactor was replaced with argon, after which dichloroethane was introduced into the reactor.
- the reaction solution was heated to a temperature of 85° C. and stirred for 5 hours.
- the reaction solution was concentrated under reduced pressure, and the desired compound (7) was obtained and used in the next step without a separate purification procedure.
- step 2 The compound carbamoyl 2-chloroacetamide (8)(1 equivalent) obtained in step 2 above was placed in a reactor, and methanol was added thereto, after which a nucleophilic reagent (3 equivalents) was added thereto at 0° C. The solution was stirred for 30 minutes at 0° C., and then stirred overnight at room temperature. The reaction was terminated by addition of H 2 O, and the reaction solution was extracted with ethyl acetate. The organic layer was dried with MgSO 4 , filtered, and then concentrated under reduced pressure. The concentrated compound was subjected to column chromatography to obtain the desired compound (6).
- step 1 of Preparation Example 1 was performed using 5-phenyl-2H-tetrazole as a nucleophilic reagent.
- Step 3 Preparation of N-((4-bromo-3-methoxyphenyl)carbamoyl)-2-(5-phenyl-2H-tetrazol-2-yl)acetamide (5a)
- Step 1 This step was performed in the same manner as step 1 of Example 1.
- Step 2 This step was performed in the same manner as step 2 of Example 1.
- step 3 of Example 1 This step was performed in the same manner as step 3 of Example 1, except that 4-phenoxyaniline (1 equivalent) (62.9 mg, 0.340 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5b) (91.5 mg, 65%).
- Step 1 This step was performed in the same manner as step 1 of Example 1.
- Step 2 This step was performed in the same manner as step 2 of Example 1.
- Step 3 This step was performed in the same manner as step 3 of Example 1, except that 4-methoxybenzylamine (1 equivalent) (46.5 mg, 0.340 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5b) (87 mg, 70%).
- Step 1 This step was performed in the same manner as step 1 of Example 1.
- Step 2 This step was performed in the same manner as step 2 of Example 1.
- Step 3 This step was performed in the same manner as step 3 of Example 1, except that tryptamine (1 equivalent) (54.4 mg, 0.340 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5c) (103 mg, 78%).
- Step 1 This step was performed in the same manner as step 1 of Example 1.
- Step 2 This step was performed in the same manner as step 2 of Example 1.
- Step 3 This step was performed in the same manner as step 3 of Example 1, except that 2,4-dimethoxyaniline (1 equivalent) (52.0 mg, 0.340 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5e) (103 mg, 79%).
- Step 1 This step was performed in the same manner as step 1 of Example 1.
- Step 2 This step was performed in the same manner as step 2 of Example 1.
- Step 3 This step was performed in the same manner as step 3 of Example 1, except that 4-(benzyloxy)aniline (1 equivalent) (116.0 mg, 0.492 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5f) (147 mg, 70%).
- Step 1 This step was performed in the same manner as step 1 of Example 1.
- Step 2 This step was performed in the same manner as step 2 of Example 1.
- Step 3 This step was performed in the same manner as step 3 of Example 1, except that 2-fluoroaniline (1 equivalent) (0.049 mg, 0.51 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5g) (121 mg, 70%).
- Step 1 The process described in step 1 of Preparation Example 1 was performed using sesamol as a nucleophilic reagent.
- Step 2 This step was performed in the same manner as step 2 of Example 1, except that 2-(benzo[d][1,3]dioxol-5-yloxy)acetamide (2i) (60 mg, 0.335 mM) was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetamide (2a).
- Step 3 This step was performed in the same manner as step 3 of Example 1, except that 2-(benzo[d][1,3]dioxol-5-yloxy)acetyl isocyanate (3i) obtained in step 2 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetyl isocyanate (3a), and 3-fluoropyridin-2-amine (1 equivalent) (38.7 mg, 0.345 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5i) (90.8 mg, 79%).
- 2-(benzo[d][1,3]dioxol-5-yloxy)acetyl isocyanate (3i) obtained in step 2 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetyl isocyanate (3a), and 3-fluoropyridin-2-amine (1 equivalent) (38.7 mg,
- Step 1 This step was performed in the same manner as step 1 of Example 8.
- Step 2 This step was performed in the same manner as step 2 of Example 8.
- Step 3 This step was performed in the same manner as step 3 of Example 8, except that 4-bromo-3-methoxyaniline (69.8 mg, 0.345 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5j) (96 mg, 66%).
- Step 1 This step was performed in the same manner as step 1 of Example 8.
- Step 2 This step was performed in the same manner as step 2 of Example 8.
- Step 3 This step was performed in the same manner as step 3 of Example 8, except that 4-phenoxyaniline (64 mg, 0.345 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5k) (98 mg, 70%).
- Step 1 This step was performed in the same manner as step 1 of Example 8.
- Step 2 This step was performed in the same manner as step 2 of Example 8.
- Step 3 This step was performed in the same manner as step 3 of Example 8, except that (4-methoxyphenyl) methanamine (47.4 mg, 0.345 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5l) (86.5 mg, 70%).
- Step 1 This step was performed in the same manner as step 1 of Example 8.
- Step 2 This step was performed in the same manner as step 2 of Example 8.
- Step 3 This step was performed in the same manner as step 3 of Example 8, except that tryptamine (55.3 mg, 0.345 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5m) (92 mg, 70%).
- Step 1 This step was performed in the same manner as step 1 of Example 8.
- Step 2 This step was performed in the same manner as step 2 of Example 8.
- Step 3 This step was performed in the same manner as step 3 of Example 8, except that 2,4-dimethoxyaniline (52.9 mg, 0.345 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5n) (90 mg, 70%).
- Step 1 This step was performed in the same manner as step 1 of Example 8.
- Step 2 This step was performed in the same manner as step 2 of Example 8.
- Step 3 This step was performed in the same manner as step 3 of Example 8, except that 4-(benzyloxy)aniline HCl (81.4 mg, 0.345 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (50) (60.9 mg, 42%).
- Step 1 This step was performed in the same manner as step 1 of Example 8.
- Step 2 This step was performed in the same manner as step 2 of Example 8.
- Step 3 This step was performed in the same manner as step 3 of Example 8, except that 2-fluoroaniline (0.033 ml, 0.345 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5p) (43.5 mg, 38%).
- Step 1 The process described in step 1 of Preparation Example 1 was performed using 2-Methoxyphenol as a nucleophilic reagent.
- Step 2 This step was performed in the same manner as step 2 of Example 1, except that 2-(2-methoxyphenoxy) acetamide (2q) (40 mg, 0.2207 mM) was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetamide (2a).
- Step 3 This step was performed in the same manner as step 3 of Example 1, except that 2-(2-methoxyphenoxy)acetyl isocyanate (3q) obtained in step 2 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetyl isocyanate (3a), and 3-fluoropyridin-2-amine (1 equivalent) (24.7 mg, 0.221 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5q) (17 mg, 24%).
- Step 1 This step was performed in the same manner as step 1 of Example 16.
- Step 2 This step was performed in the same manner as step 2 of Example 16.
- Step 3 This step was performed in the same manner as step 3 of Example 16, except that 4-bromo-3-methoxyaniline (44.6 mg, 0.221 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5r) (63 mg, 70%).
- Step 1 This step was performed in the same manner as step 1 of Example 16.
- Step 2 This step was performed in the same manner as step 2 of Example 16.
- Step 3 This step was performed in the same manner as step 3 of Example 15, except that 4-phenoxyaniline (51.1 mg, 0.276 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5s) (62 mg, 57%).
- Step 1 This step was performed in the same manner as step 1 of Example 16.
- Step 2 This step was performed in the same manner as step 2 of Example 16.
- Step 3 This step was performed in the same manner as step 3 of Example 16, except that 4-methoxyphenyl)methanamine (0.029 ml, 0.221 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5t) (31 mg, 41%).
- Step 1 This step was performed in the same manner as step 1 of Example 16.
- Step 2 This step was performed in the same manner as step 2 of Example 16.
- Step 3 This step was performed in the same manner as step 3 of Example 16, except that tryptamine (53 mg, 0.331 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5u) (94.6 mg, 76%).
- Step 1 This step was performed in the same manner as step 1 of Example 16.
- Step 2 This step was performed in the same manner as step 2 of Example 16.
- Step 3 This step was performed in the same manner as step 3 of Example 16, except that 2,4-dimethoxyaniline (51 mg, 0.331 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5v) (83.4 mg, 70%).
- Step 1 This step was performed in the same manner as step 1 of Example 16.
- Step 2 This step was performed in the same manner as step 2 of Example 16.
- Step 3 This step was performed in the same manner as step 3 of Example 16, except that 4-(benzyloxy)aniline (52 mg, 0.221 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5w) (56.5 mg, 63%).
- Step 1 This step was performed in the same manner as step 1 of Example 16.
- Step 2 This step was performed in the same manner as step 2 of Example 16.
- Step 3 This step was performed in the same manner as step 3 of Example 16, except that 2-fluoroaniline (0.033 ml, 0.331 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5x) (74 mg, 70%).
- Step 1 The process described in step 1 of Preparation Example 1 was performed using 3,5-bis(trifluoromethyl)phenol as a nucleophilic reagent.
- Step 2 This step was performed in the same manner as step 2 of Example 1, except that 2-(3,5-bis(trifluoromethyl)phenoxy)acetamide (2y) (70 mg, 0.244 mM) obtained in step 1 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetamide (2a).
- Step 3 This step was performed in the same manner as step 3 of Example 1, except that 2-(3,5-bis(trifluoromethyl)phenoxy)acetyl isocyanate (3y) obtained in step 2 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetyl isocyanate (3a), and 3-fluoropyridin-2-amine (1 equivalent) (27 mg, 0.243 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5y) (72 mg, 70%).
- Step 1 This step was performed in the same manner as step 1 of Example 24.
- Step 2 This step was performed in the same manner as step 2 of Example 24.
- Step 3 This step was performed in the same manner as step 3 of Example 24, except that 4-bromo-3-methoxyaniline (52.5 mg, 0.259 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5z) (29 mg, 22%).
- Step 1 This step was performed in the same manner as step 1 of Example 24.
- Step 2 This step was performed in the same manner as step 2 of Example 24.
- Step 3 This step was performed in the same manner as step 3 of Example 24, except that 4-phenoxyaniline (45.0 mg, 0.243 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5aa) (98 mg, 81%).
- Step 1 This step was performed in the same manner as step 1 of Example 24.
- Step 2 This step was performed in the same manner as step 2 of Example 24.
- Step 3 This step was performed in the same manner as step 3 of Example 24, except that 4-methoxyphenyl)methanamine (0.031 8 ml, 0.243 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5ab) (66.7 mg, 61%).
- Step 1 This step was performed in the same manner as step 1 of Example 24.
- Step 2 This step was performed in the same manner as step 2 of Example 24.
- Step 3 This step was performed in the same manner as step 3 of Example 24, except that tryptamine (33.5 mg, 0.209 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5ac) (69 mg, 70%).
- Step 1 This step was performed in the same manner as step 1 of Example 24.
- Step 2 This step was performed in the same manner as step 2 of Example 24.
- Step 3 This step was performed in the same manner as step 3 of Example 24, except that 2,4-dimethoxyaniline (40 mg, 0.261 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5ad) (60 mg, 49%).
- Step 1 This step was performed in the same manner as step 1 of Example 24.
- Step 2 This step was performed in the same manner as step 2 of Example 24.
- Step 3 This step was performed in the same manner as step 3 of Example 24, except that 4-(benzyloxy)aniline HCl (61 mg, 0.260 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5ae) (32 mg, 24%).
- Step 1 This step was performed in the same manner as step 1 of Example 24.
- Step 2 This step was performed in the same manner as step 2 of Example 24.
- Step 3 This step was performed in the same manner as step 3 of Example 24, except that 2-fluoroaniline (0.025 ml, 0.260 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5af) (84 mg, 76%).
- Step 1 The process described in step 1 of Preparation Example 1 was performed using 3-bromophenol as a nucleophilic reagent.
- Step 2 This step was performed in the same manner as step 2 of Example 1, except that 2-(3-bromophenoxy)acetamide (2ag) (36 mg, 0.158 mM) obtained in step 1 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetamide (2a).
- Step 3 This step was performed in the same manner as step 3 of Example 1, except that 2-(3-bromophenoxy)acetyl isocyanate (3ag) obtained in step 2 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetyl isocyanate (3a), and 4-bromo-3-methoxyaniline (1 equivalent) (27 mg, 0.243 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5ag) (84 mg, 76%).
- Step 1 This step was performed in the same manner as step 1 of Example 32.
- Step 2 This step was performed in the same manner as step 2 of Example 32.
- Step 3 This step was performed in the same manner as step 3 of Example 32, except that 2,4-dimethoxyaniline (1 equivalent) (0.025 ml, 0.260 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5ah) (52 mg, 49%).
- step 1 of Preparation Example 1 was performed using 2,3-dimethylphenol as a nucleophilic reagent.
- step 1 was performed in the same manner as step 2 of Example 1, except that 2-(3,5-dimethylphenoxy)acetamide (2aj) (50 mg, 0.279 mM) obtained in step 1 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetamide (2a).
- step 2 was performed in the same manner as step 3 of Example 1, except that 2-(2,3-dimethylphenoxy)acetyl isocyanate) (3aj) obtained in step 2 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetyl isocyanate (3a), and 2-fluoroaniline (1 equivalent) (0.0224 ml, 0.233 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5aj) (44.2 mg, 50%).
- step 1 of Preparation Example 1 was performed using 4-(benzyloxy)phenol as a nucleophilic reagent.
- step 1 was performed in the same manner as step 2 of Example 1, except that 2-(4-(benzyloxy)phenoxy)acetamide (2ak) (50 mg, 0.194 mM) obtained in step 1 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetamide (2a).
- step 2 was performed in the same manner as step 3 of Example 1, except that 2-(4-(benzyloxy)phenoxy)acetyl isocyanate (3ak) obtained in step 2 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetyl isocyanate (3a), and 2-fluoroaniline (1 equivalent) (0.0156 ml, 0.162 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5ak) (27.6 mg, 36%).
- 2-(4-(benzyloxy)phenoxy)acetyl isocyanate (3ak) obtained in step 2 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetyl isocyanate (3a), and 2-fluoroaniline (1 equivalent) (0.0156 ml, 0.162 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophil
- Step 1 This step was performed in the same manner as step 1 of Example 33.
- Step 2 This step was performed in the same manner as step 2 of Example 33.
- Step 3 Preparation of tert-butyl 4-(2-(3-(2-fluorophenyl)ureido)-2-oxoethyl)piperazine-1-carboxylate
- Step 1 The process described in step 1 of Preparation Example 2 was performed.
- Step 2 The process described in step 2 of Preparation Example 2 was performed using 2-Fluoroaniline as a nucleophilic reagent.
- Step 3 Methanol (4 ml) was added to the compound (2-chloro-N-((2-fluorophenyl)carbamoyl)acetamide)(1 equivalent)(191 mg, 0.830 mM) obtained in step 2, and then the reactor was set to 80° C., after which morpholine (3 equivalents) (217 mg, 2.49 mM) was added and the solution was stirred for 30 minutes. The reaction solution was stirred overnight at room temperature. The reaction was terminated by addition of H 2 O to the reaction solution, and the reaction solution was extracted with ethyl acetate. The organic layer was dried with MgSO 4 , filtered, and then concentrated under reduced pressure.
- integrin ⁇ EIIb ⁇ 3 present in the platelet cell membrane, and this integrin binds to fibrinogen after being activated by talin.
- integrin ⁇ EIIb ⁇ 3 was first stably expressed in the CHO cell line using lentivirus, thereby constructing a CHO/ ⁇ EIIb ⁇ 3 cell line.
- the constructed cell line was cultured in a fibrinogen-coated 96-well plate for 1 hour and washed, after which the amount of remaining cells was measured to evaluate the efficacy of a talin antagonist candidate.
- a cell counting kit-8 (CCK-8) was used to measure the activity of dehydrogenase present in the remaining cells.
- CCK-8 changed from yellow to orange ( FIG. 1 ).
- the absorbance at a wavelength of 450 nm was measured with a plate reader. This enabled easy, fast and reliable high-throughput screening.
- FIG. 3 shows the concentration-dependent effects of KCH-1513 and KCH-1521 on inhibition of the binding between the CHO/ ⁇ EIIb ⁇ 3 cell line and fibrinogen.
- FIG. 3 like FIG.
- KCH-1513 and KCH-1521 showed an inhibitory effect of at least 50% at a concentration ranging from 0.02 to 0.07 mM.
- a talin antagonist candidate was added to the talin protein immobilized on a sensor chip, and the affinity constant between the two substances was measured by surface plasmon resonance (hereinafter referred to as ‘SPR’) spectrometry.
- SPR surface plasmon resonance
- Talin is divided into an N-terminal head domain and a C-terminal rod domain, and the head domain is further divided into four subdomains, F0, F1, F2 and F3. Among them, F3 is known as an integrin binding site. Thus, 6 ⁇ His-tagged F2F3 protein containing F3 was isolated and purified. As a sensor chip for immobilizing the talin protein, HTEPBE10PO1 (Biorad) was used. SPR was measured using ProteONTM XPR36 (Biorad).
- the compounds KCH-1513 and KCH-1521 were measured to have affinity constants of 9.33 ⁇ 10 ⁇ 3 M and 2.71 ⁇ 10 ⁇ 4 M, respectively, and it was shown that the talin antagonist candidates did bind to the talin protein in a concentration-dependent manner.
- Platelets isolated from human peripheral blood were treated with TRAP (32 ⁇ M), ADP (6.5 ⁇ M) and arachidonic acid (AA; 0.5 mM), which are platelet aggregation agonists, in combination with different concentrations (0 ⁇ M, 10 ⁇ M and 30 ⁇ M) of various compounds (KCH-1513 and KCH-1521), and inhibition of aggregation of the platelets was compared ( FIG. 6 ). As a result, it could be seen that KCH-1513 and KCH-1521 had platelet aggregation inhibitory activities similar to that of a positive control.
- Platelets isolated from human peripheral blood which has been administered with conventional platelet inhibitors (cyclooxygenase inhibitor and ADP receptor blocker), were treated with ADP (6.5 ⁇ M), TRAP (32 ⁇ M) and arachidonic acid (AA; 0.5 mM), which are platelet aggregation agonists, in combination with KCH-1526, and inhibition of aggregation of the platelets was compared ( FIG. 8 ).
- ADP 6.5 ⁇ M
- TRAP 32 ⁇ M
- AA arachidonic acid
- treatment with the representative novel compound KCH-1526 exhibited similar or better platelet aggregation inhibitory activity than those of the conventional platelet inhibitors (cyclooxygenase inhibitor and ADP receptor blocker) in the platelets treated with the platelet aggregation agonists (ADP, TRAP and arachidonic acid).
- N-acylurea derivative 2 g
- Lactose 1 g
- N-acylurea derivative 100 mg
- Lactose 100 mg
- Magnesium stearate 2 mg.
- the above components were mixed with one another and compressed into a tablet according to a conventional tablet preparation method, thereby preparing a tablet formulation.
- N-acylurea derivative 100 mg
- Lactose 100 mg
- Magnesium stearate 2 mg.
- the above components were mixed with one another and filled into a gelatin capsule according to a conventional capsule preparation method, thereby preparing a capsule formulation.
- N-acylurea 10 ⁇ g/ml
- a 2-ethoxypropionic acid derivative was dissolved in a suitable volume of sodium chloride BP for injection, the pH of the resultant solution was adjusted to pH3.5 with dilute hydrochloric acid BP, and then the solution was made to volume with sodium chloride BP for injection and thoroughly mixed.
- the solution was filled into 5 ml type I clear glass ampoules which were then sealed under a headspace of air by fusion of the glass, and then sterilized by autoclaving at 120° C. for not less than 15 minutes, thereby preparing an injectable liquid formulation.
- the N-acylurea derivative according to the present invention can inhibit platelet aggregation by inhibiting the activity of talin in the intracellular matrix, and thus can be useful for the prevention or treatment of cardiovascular disease.
Abstract
The present invention relates to a novel N-acylurea derivative and the use thereof for the prevention or treatment of cardiovascular disease, and more particularly to a novel N-acylurea derivative, a pharmaceutical composition for prevention or treatment of cardiovascular disease, which contains the N-acylurea derivative as an active ingredient, and a method of preparing the N-acylurea derivative. The N-acylurea derivative according to the present invention can inhibit platelet aggregation by inhibiting the activity of talin in the intracellular matrix, and thus can be useful for the prevention or treatment of cardiovascular disease.
Description
- This is a continuation under 35 USC § 120 of U.S. patent application Ser. No. 16/094,826 filed Oct. 18, 2018, which in turn is a U.S. national phase under 35 U.S.C. § 371 of International Patent Application No. PCT/KR16/15122 filed Dec. 22, 2016, which in turn claims priority under 35 USC § 119 of Korean Patent Application No. 10-2016-0050817 filed Apr. 26, 2016. The disclosures of all such applications are hereby incorporated herein by reference in their respective entireties, for all purposes.
- The applicants acknowledge the financial support of the following grants involving work related to the present disclosure: (1) the research program entitled “Preclinical Development of Novel Antiplatelet Drugs Using Integrin-Talin Signaling Pathway” was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Project grant number: HI14C0209), and managed by KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION from Jun. 1, 2014 to May 31, 2018; and (2) the research program entitled “Novel anti-platelet agent development and efficacy verification targeting new mechanism of Glycoprotein IIb/IIIa inside-out signaling” was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF), funded by the Ministry of Science & ICT (Project grant number: NRF-2018M3A9A8017949), and managed by KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION from Apr. 1, 2018 to Dec. 31, 2019.
- The present invention relates to a novel N-acylurea derivative and the use thereof for the prevention or treatment of cardiovascular disease, and more particularly to a novel N-acylurea derivative, a pharmaceutical composition for preventing or treating cardiovascular disease, which contains the N-acylurea derivative as an active ingredient, and a method of preparing the N-acylurea derivative.
- Talin molecule which is one of the cytoskeletal components is a cytoplasmic protein. It is known that the talin molecule links integrin to the cytoskeleton directly or indirectly by interaction with vinculin and α-actinin (Alan D. Michelson, Platelets, Second Edition, 2006).
- In the report on abnormalities in the talin molecule network, it was reported that the knockout of the talin molecule makes it impossible to develop into a normal individual after fertilization and leads to death within 8 days after fertilization, indicating that the talin molecule is a developmentally important molecule (Dev Dyn., 219:560, 2000).
- Studies on the relationship between talin molecules and platelets indicated that the activities of integrin and talin molecules play an important role in the adhesion and aggregation of platelets. Adhesion and aggregation of platelets occur due to vascular endothelial wound, and the activation of integrin by talin molecules occurs. On the contrary, it is known that talin-deficient platelets do not induce activation of integrin, and thus reduce thrombosis (J Exp. Med., 204(13):3113, 2007). In addition, it was reported that the knockout of talin molecules in megakaryocytes which are platelet precursors results in inhibition of talin-induced integrin activation, causing continuous hemorrhage (J Exp. Med, 204(13):3103, 2007). Therefore, the regulation of talin molecule activity can lead to the inhibition of platelet aggregation and the reduction of thrombosis and bleeding.
- Accordingly, the present inventors have made extensive efforts to develop a substance capable of treating and preventing talin-related diseases by reducing talin expression, and as a result, have synthesized novel N-acylurea derivatives and have found that the novel N-acylurea derivatives exhibit the effect of inhibiting platelet aggregation by inhibiting the activity of talin and effectively regulating cellular morphological changes and growth, thereby completing the present invention.
- It is an object of the present invention to provide a novel N-acylurea derivative or a pharmaceutically acceptable salt thereof.
- Another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of cardiovascular disease, comprising the N-acyl urea derivative or the pharmaceutically acceptable salt thereof as an active ingredient.
- Still another object of the present invention is to provide a method of preparing the N-acylurea derivative or the pharmaceutically acceptable salt thereof.
- To achieve the above objects, the present invention provides a novel N-acylurea derivative which is a compound represented by Formula 1 below, or a pharmaceutically acceptable salt thereof:
- wherein
- R1 is hydrogen, halogen, hydroxy, C1-6 alkyl, C1-6 haloaklyl, C6-12 aryl, C1-12 heteroaryl, C1-12 heterocyclyl, C1-6 alkyl linked by heteroatom, or a C6-12 aryl linked by heteroatom, C1-12 heteroaryl or C1-12 heterocyclyl, wherein the aryl, heteroaryl or heterocyclyl may be unsubstituted or substituted, and the heteroatom is selected from N, O and S;
- R2 is hydrogen, C1-6 alkyl, C1-6 haloalkyl, C6-12 aryl, C1-12 heteroaryl, C1-12 heterocyclyl, C2-20 alkylene-C6-12 aryl, C2-20 alkylene-C1-12 heteroaryl, or C2-20 alkylene-C1-12 heterocyclyl, wherein the aryl, heteroaryl or heterocyclyl may be unsubstituted or substituted, and the heteroatom is selected from N, O and S; and
- R3 and R4 are each independently hydrogen, C1-6 alkyl or C1-6 haloalkyl.
- The present invention also provides a pharmaceutical composition for the prevention or treatment of cardiovascular disease, which contains the novel N-acylurea derivative or the pharmaceutically acceptable salt thereof as an active ingredient.
- The present invention also provides a method of preparing the novel N-acyl urea derivative represented by above
Formula 1, or the pharmaceutically acceptable salt thereof, comprising: (a) obtaining acetamide by mixing and reacting 2-chloroacetamide, N,N-dimethylformamide, potassium carbonate and a nucleophilic reagent in a reactor, terminating a reaction by addition of water, followed by concentrating; (b) obtaining acetyl isocyanate by adding oxalyl chloride to the obtained acetamide, adding dichloroethane and heating and stirring, followed by concentrating; and (c) obtaining a compound by adding methylene chloride to the obtained acetyl isocyanate, adding and reacting a nucleophilic reagent, followed by concentrating. - The present invention also provides a method of preparing the N-acyl urea derivative of
above Formula 1, or the pharmaceutically acceptable salt thereof, comprising: (a) obtaining 2-chloroacetyl isocyanate by mixing 2-chloroacetamide and oxalyl chloride in a reactor, adding dichloroethane and heating and stirring, followed by concentrating; (b) obtaining carbamoyl 2-chloroacetamide by adding methylene chloride to the obtained 2-chloroacetyl isocyanate, and then adding a nucleophilic reagent and reacting, followed by concentrating; and (c) obtaining N-acylurea derivative by adding methanol to the obtained carbamoyl 2-chloroacetamide, adding and reacting a nucleophilic reagent while stirring, extracting an N-acylurea derivative using an organic solvent. -
FIG. 1 shows the results of Western blot analysis performed to confirm the effect of a compound of the present invention (a compound of Preparation Example 30 or a compound of Preparation Example 31) on the inhibition of β-catenin expression in HEK293 cells in which the Wnt/β-catenin pathway was activated by treatment with Wnt-3a CM.FIG. 1 is a schematic view showing an experimental method for high-throughput screening of thrombosis inhibitory candidates in Example 38 of the present invention. -
FIG. 2 shows the results of screening thrombosis inhibitory candidates according to Example 38 of the present invention. Cells expressing platelet integrin αIIbβ3 were incubated with 0.2 mM of candidates, and the binding between the cells and fibrinogen was verified according to the experimental method shown inFIG. 1 . InFIG. 2 , 0% is a negative control and represents the degree to which cells adhere to a surface coated with bovine serum albumin (BSA) instead of fibrinogen, and 100% is a positive control and represents the degree to which cells adhere to fibrinogen in the absence of any candidate. The ability of candidates to inhibit fibrinogen binding was normalized to 100%, and the mean and standard error of three experiments are graphically shown. -
FIG. 3 shows the results of testing the concentration-dependent inhibitory activity of effective representative thrombosis inhibitory candidates in Example 38 of the present invention. -
FIG. 4 shows the results of measuring the binding affinity of talin antagonist candidates for talin protein by surface plasmon resonance spectroscopy in Example 39 of the present invention. -
FIG. 5 shows the results of analyzing the platelet aggregation inhibitory effects of KCH-1513 and KCH-1521 in Example 40 of the present invention. -
FIG. 6 depicts graphs showing the results obtained by treating human peripheral blood with platelet aggregation agonists (TRAP, ADP and arachidonic acid), and then treating the blood again with compounds of the present invention, and comparing and quantifying the inhibition of platelet aggregation, in Example 41 of the present invention in order to compare the platelet aggregation inhibitory activities of various compounds in human peripheral blood. -
FIG. 7 schematically shows a mechanism by which the novel N-acylurea derivative of the present invention acts. -
FIG. 8 depicts graphs showing the results obtained by treating human peripheral blood (which has been administered with conventional platelet inhibitors) with platelet aggregation agonists (TRAP, ADP and arachidonic acid), and then treating the blood again with compounds of the present invention, and comparing and quantifying the inhibition of platelet aggregation, in Example 42 of the present invention in order to compare the platelet aggregation inhibitory activities of various compounds in human peripheral blood. - In one aspect, the present invention is directed to an N-acylurea derivative represented by Formula 1 below or a pharmaceutically acceptable salt thereof:
- wherein
- R1 is hydrogen, halogen, hydroxy, C1-6 alkyl, C1-6 haloaklyl, C6-12 aryl, C1-12 heteroaryl, C1-12 heterocyclyl, C1-6 alkyl linked by heteroatom, or a C6-12 aryl linked by heteroatom, C1-12 heteroaryl or C1-12 heterocyclyl, wherein the aryl, heteroaryl or heterocyclyl may be unsubstituted or substituted, and the heteroatom is selected from N, O and S;
- R2 is hydrogen, C1-6 alkyl, C1-6 haloalkyl, C6-12 aryl, C1-12 heteroaryl, C1-12 heterocyclyl, C2-20 alkylene-C6-12 aryl, C2-20 alkylene-C1-12 heteroaryl, or C2-20 alkylene-C1-12 heterocyclyl, wherein the aryl, heteroaryl or heterocyclyl may be unsubstituted or substituted, and the heteroatom is selected from N, O and S; and R3 and R4 are each independently hydrogen, C1-6 alkyl or C1-6 haloalkyl.
- As used herein, the term “C1-6 alkyl” refers to a monovalent linear or branched saturated hydrocarbon radical (or moiety), consisting solely of carbon and hydrogen atoms, having one to six carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, n-hexyl and the like. Examples of “branched alkyl” include isopropyl, isobutyl, tert-butyl and the like.
- The term “C1-6 haloalkyl” means a C1-6 alkyl as defined herein wherein at least one of the hydrogen atoms of the alkyl group has been substituted by the same or different halogen atoms. Examples of haloalkyl include —CH2Cl, —CH2CF3, —CH2CCl3, perfluoroalkyl (e.g., —CF3) and the like.
- The term “C2-20 alkylene” means a linear saturated divalent hydrocarbon radical having 2 to 20 carbon atoms, or a branched saturated divalent hydrocarbon radical having 3 to 20 carbon atoms, e.g., methylene, ethylene, 2,2-dimethylethylene, propylene, 2-methylpropylene, butylene, pentylene, and the like.
- The term “C1-6 alkoxy” means to a moiety of the formula —O—C1-6 alkyl. Examples of C1-6 alkoxy moieties include, but are not limited to, methoxy, ethoxy, isopropoxy, tert-butoxy, and the like.
- The term “C6-12 aryl” means a monovalent cyclic aromatic hydrocarbon radical having 6 to 12 carbon atoms and consisting of a mono-, bi- or tricyclic aromatic ring. The aryl group may be substituted or unsubstituted as defined herein. In one embodiment, the aryl group may be a substituted or unsubstituted phenyl group, or a substituted or unsubstituted naphthyl group. In particular, in one embodiment, the aryl group is a substituted or unsubstituted phenyl group.
- The term “C1-12 heteroaryl” means a monocyclic, bicyclic or tricyclic radical of 5 to 12, specifically 6 to 10 ring atoms having at least one aromatic ring containing one, two, or three ring heteroatoms selected from N, O, and S, the remaining ring atoms being C, with the understanding that the attachment point of the heteroaryl radical will be on an aromatic ring. The heteroaryl ring may be a 5- or 6-membered monocyclic ring containing one, two, or three ring heteroatoms selected from N, O, and S, the remaining ring atoms being C. The heteroaryl ring may be substituted or unsubstituted as defined herein. Examples of heteroaryl moieties include, but are not limited to, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, thienyl (i.e., thiopenyl), furanyl, pyranyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolinyl, iso quinolinyl, benzofuryl (i.e., benzofuranyl), benzothiophenyl, benzothiopyranyl, benzimidazolyl, benzoxazolyl, benzooxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzopyranyl, indolyl, isoindolyl, triazolyl, triazinyl, quinoxalinyl, purinyl, quinazolinyl, quinolizinyl, naphthyridinyl, pteridinyl, carbazolyl, azepinyl, diazepinyl, acridinyl, and the like, which may be each substituted or unsubstituted. Examples of preferable heteroaryl moieties includes pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, indolyl, pyridinyl, pyrimidinyl, pyrazinyl, and pyridazinyl, which may be each substituted or unsubstituted. In one embodiment, the heteroaryl moiety is triazolyl, tetrazolyl, pyridinyl, or indolyl, which may be each substituted or unsubstituted as defined herein.
- The term “C1-12 heterocyclyl” means a 4- to 9-membered saturated or partially unsaturated carbocyclic ring containing, in addition to carbon atoms, one, two, or three ring heteroatoms selected from N, O and S. Here, the two rings share two common ring atoms. That is, the bridge that separates the two rings is a single bond or a 1- or 2-membered chain. The heterocyclyl ring may be substituted or unsubstituted as defined herein. Examples of heterocyclyl moieties include, but are not limited to, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyranyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholin-4-yl, azepanyl, diazepanyl, homopiperazinyl, oxazepanyl, dihydroindolyl, dihydrofuryl, dihydroimidazolinyl, dihydrooxazolyl, tetrahydropyridinyl, dihydropyranyl, or benzodioxolyl. In one embodiment, heterocyclyl is piperazinyl, morpholinyl, benzodioxolyl, or dihydroindolyl, which may be each substituted or unsubstituted as defined herein. The term “aryl, heteroaryl or heterocyclyl linked by heteroatom” refers to aryl, heteroaryl or heterocyclyl linked by the
heteroatom 0, S or Se. In one embodiment, the heteroatom is O or S. - In the
above Formula 1, R1 is hydrogen, halogen, hydroxy, C1-6 alkyl, C1-6 haloaklyl, C6-12 aryl, C1-12 heteroaryl, C1-12 heterocyclyl, C1-6 alkyl linked by heteroatom, or a C6-12 aryl linked by heteroatom, C1-12 heteroaryl or C1-12 heterocyclyl, wherein the aryl, heteroaryl or heterocyclyl may be unsubstituted or substituted with one to three substituents selected from the group consisting of halogen, hydroxy, C1-6 alkyl, C1-6 haloaklyl, C1-6 alkoxy, C1-6 haloalkoxy, —C1-6 alkoxy-C1-6 alkyl, C1-6 alkoxycarbonyl, —O-aryl, —O-heteroaryl, and —O—C2-20 alkylene-aryl. - In one embodiment, R1 is tetrazolyl, piperazinyl, morpholinyl, phenyl linked by O, or benzodioxolyl linked by O, wherein the tetrazolyl, piperazinyl, morpholinyl or benzodioxolyl may be unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of halogen, C1-6 haloalkyl, C1-6 alkoxy, C1-6 alkoxycarbonyl, phenoxy, and —O—C2-20 alkylene-phenyl. Specifically, the tetrazolyl, piperazinyl, morpholinyl or benzodioxolyl may be substituted with 1 to 3 substituents selected from the group consisting of F, Br, CF3, methoxy, t-butoxycarbonyl, phenoxy, and —O—CH2-phenyl.
- In
Formula 1 above, R2 is hydrogen, C1-6 alkyl, C1-6 haloalkyl, C6-12 aryl, C1-12 heteroaryl, C1-12 heterocyclyl, C2-20 alkylene-C6-12 aryl, C2-20 alkylene-C1-12 heteroaryl, or C2-20 alkylene-C1-12 heterocyclyl, wherein the aryl, heteroaryl or heterocyclyl may be unsubstituted or substituted with one to three substituents selected from the group consisting of halogen, hydroxy, C1-6 alkyl, C1-6 haloaklyl, C1-6 alkoxy, C1-6 haloalkoxy, —C1-6 alkoxy-C1-6 alkyl, C1-6 alkoxycarbonyl, —O-aryl, —O-heteroaryl, and —O—C2-20 alkylene-C6-12 aryl. - In one embodiment, R2 is phenyl, pyridinyl, C2-20 alkylene-phenyl, C2-20 alkylene-indolyl, or C2-20 alkylene-dihydroindolyl, wherein the phenyl, pyridinyl, indolyl, or dihydroindolyl may be unsubstituted or substituted with one to three substituents selected from the group consisting of halogen, hydroxy, C1-6 alkyl, C1-6 haloaklyl, C1-6 alkoxy, C1-6 haloalkoxy, —C1-6 alkoxy-C1-6 alkyl, —O-phenyl, and −0-C2-20 alkylene-phenyl.
- In one embodiment, R2 is phenyl, pyridinyl, C2-6 alkylene-phenyl, C2-6 alkylene-indolyl, or C2-6 alkylene-dihydroindolyl, wherein the phenyl, pyridinyl, indolyl, or dihydroindolyl may be unsubstituted or substituted with one to three substituents selected from the group consisting of halogen, C1-6 alkoxy, phenoxy, and −O—C2-6 alkylene-phenyl. Specifically, the phenyl, pyridinyl, indolyl, or dihydroindolyl may be substituted with 1 to 3 substituents selected from the group consisting of F, Br, methoxy, phenoxy, and —O—CH2-phenyl.
- In
Formula 1 above, R3 and R4 are each independently hydrogen, C1-6 alkyl, or C1-6 haloalkyl. - In one embodiment, R3 and R4 are each hydrogen.
- Specific examples of the novel N-acylurea derivative which is a compound represented by the
formula 1 of the present invention include: - (1) N-((4-bromo-3-methoxyphenl)carbamoyl)-2-(5-phenyl-2H-tetrazol-2-yl)acetamide;
- (2) N-((4-phenoxyphenyl)carbamoyl)-2-(5-phenyl-2H-tetrazol-2-yl)acetamide;
- (3) N-((4-methoxybenzyl)carbamoyl)-2-(5-phenyl-2H-tetrazol-2-yl)acetamide;
- (4) N-((2-(3a,7a-dihydro-1H-indol-3-yl)ethyl)carbamoyl)-2-(5-phenyl-2H-tetrazol-2-yl)acetamide);
- (5) N-((2,4-dimethoxyphenyl)carbamoyl)-2-(5-phenyl-2H-tetrazol-2-yl)acetamide;
- (6) N-((4-(benzyloxy)phenyl)carbamoyl)-2-(5-phenyl-2H-tetrazol-2-yl)acetamide;
- (7) N-((2-fluorophenyl)carbamoyl)-2-(5-phenyl-2H-tetrazol-2-yl)acetamide;
- (8) 2-(benzo[d][1,3]dioxol-5-yloxy)-N-((3-fluoropyridin-2-yl)carbamoyl)acetamide;
- (9) 2-(benzo[d][1,3]dioxol-5-yloxy)-N-((4-bromo-3-methoxyphenyl)carbamoyl)-acetamide;
- (10) 2-(benzo[d][1,3]dioxol-5-yloxy)-N-((4-phenoxyphenyl)carbamoyl)acetamide;
- (11) 2-(benzo[d][1,3]dioxol-5-yloxy)-N-((4-methoxybenzyl)carbamoyl)acetamide;
- (12) N-((2-(1H-indol-3-yl)ethyl)carbamoyl)-2-(benzo[d][1,3]dioxol-5-yloxy)-acetamide;
- (13) 2-(benzo[d][1,3]dioxol-5-yloxy)-N-((2,4-dimethoxyphenyl)carbamoyl)acetamide;
- (14) 2-(benzo[d][1,3]dioxol-5-yloxy)-N-((4-(benzyloxy)phenyl)carbamoyl)acetamide;
- (15) 2-(benzo[d][1,3]dioxol-5-yloxy)-N-((2-fluorophenyl)carbamoyl)acetamide;
- (16) N-((3-fluoropyridin-2-yl)carbamoyl)-2-(2-methoxyphenoxy)acetamide;
- (17) N-((4-bromo-3-methoxyphenyl)carbamoyl)-2-(2-methoxyphenoxy)acetamide;
- (18) 2-(2-methoxyphenoxy)-N-((4-phenoxyphenyl)carbamoyl)acetamide;
- (19) N-((4-methoxybenzyl)carbamoyl)-2-(2-methoxyphenoxy)acetamide;
- (20) N-((2-(1H-indol-3-yl)ethyl)carbamoyl)-2-(benzo[d][1,3]dioxol-5-yloxy)-acetamide;
- (21) N-((2,4-dimethoxyphenyl)carbamoyl)-2-(2-methoxyphenoxy)acetamide;
- (22) N-((4-(benzyloxy)phenyl)carbamoyl)-2-(2-methoxyphenoxy)acetamide;
- (23) N-((2-fluorophenyl)carbamoyl)-2-(2-methoxyphenoxy)acetamide;
- (24) 2-(3,5-bis(trifluoromethyl)phenoxy)-N-((3-fluoropyridin-2-yl)carbamoyl)-acetamide;
- (25) 2-(3,5-bis(trifluoromethyl)phenoxy)-N-((4-bromo-3-methoxyphenyl)carbamoyl)-acetamide;
- (26) 2-(3,5-bis(trifluoromethyl)phenoxy)-N-((4-bromo-3-methoxyphenyl)carbamoyl)-acetamide;
- (27) 2-(3,5-bis(trifluoromethyl)phenoxy)-N-((4-methoxybenzyl)carbamoyl)acetamide;
- (28) N-((2-(1H-indol-3-yl)ethyl)carbamoyl)-2-(3,5-bis (trifluoromethyl)phenoxy)-acetamide;
- (29) 2-(3,5-bis(trifluoromethyl)phenoxy)-N-((2,4-dimethoxyphenyl)carbamoyl)-acetamide;
- (30) N-((4-(benzyloxy)phenyl)carbamoyl)-2-(3,5-bis(trifluoromethyl)phenoxy)-acetamide;
- (31) 2-(3,5-bis(trifluoromethyl)phenoxy)-N-((2-fluorophenyl)carbamoyl)acetamide;
- (32) N-((4-bromo-3-methoxyphenyl)carbamoyl)-2-(3-bromophenoxy)acetamide;
- (33) 2-(3-bromophenoxy)-N-((2,4-dimethoxyphenyl)carbamoyl)acetamide;
- (34) 2-(2,3-dimethylphenoxy)-N-((2-fluorophenyl)carbamoyl)acetamide;
- (35) 2-(4-(benzyloxy)phenoxy)-N-((2-fluorophenyl)carbamoyl)acetamide;
- (36) N-((2-fluorophenyl)carbamoyl)-2-morpholinoacetamide; and
- (37) tert-butyl 4-(2-(3-(2-fluorophenyl)ureido)-2-oxoethyl)piperazine-1-carboxylate.
- The N-acylurea derivative of
Formula 1 above according to the present invention comprises a pharmaceutically acceptable salt thereof, and a hydrate and a solvate prepared therefrom. - As used herein, the compound represented by
Formula 1 designated is intended to embrace a pharmaceutically acceptable salt thereof. The pharmaceutically acceptable salt can be prepared by a salt preparation method that is commonly used in the art. - As used herein, the term “pharmaceutically acceptable salt” refers to a salt prepared from a pharmaceutically acceptable non-toxic base or acid including an inorganic or organic base and an inorganic or organic acid. The salt derived from an inorganic base is preferably aluminum, ammonium, calcium, magnesium, potassium or sodium salt. A solid salt may have one or more crystal structures, or otherwise may be in the form of a hydrate. Examples of the salt derived from a pharmaceutically acceptable non-toxic organic base include a primary, secondary or tertiary amine, a substituted amine such as a naturally-occurring substituted amine, a cyclic amine, or a basic ion exchange resin such as arginine, betaine, caffeine, choline, N,N′-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resin, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, or the like.
- When the compound of the present invention is basic, a salt thereof may be prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids. Examples of the acid include acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucic acid, nitric acid, pamoic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, p-toluene sulfonic acid, and the like. Particularly, the pharmaceutically acceptable salt may preferably be acetic, citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, fumaric, or tartaric acid.
- A hydrate of a compound represented by
Formula 1 of the present invention or a pharmaceutically acceptable salt thereof is intended to embrace a stoichiometric or non-stoichiometric amount of water bound thereto by non-covalent intermolecular forces. The hydrate may contain one or more equivalents of water, typically 1 to 5 equivalents of water. The hydrate may be prepared by crystallization of the compound represented byFormula 1 of the present invention or a pharmaceutically acceptable salt thereof in water or water-containing solvent. - A solvate of a compound represented by
Formula 1 of the present invention or a pharmaceutically acceptable salt thereof is intended to embrace a stoichiometric or non-stoichiometric amount of a solvent bound thereto by non-covalent intermolecular forces. Preferred solvents are volatile, non-toxic, and suitable for administration to humans. In another aspect, the present invention is directed to a pharmaceutical composition for the prevention or treatment of cardiovascular disease, which contains a novel N-acylurea derivative or a pharmaceutically acceptable salt thereof as an active ingredient. - The cardiovascular disease of the present invention includes, but is not limited to, hypertension, ischemic heart disease, coronary artery disease, angina pectoris, myocardial infarction, arteriosclerosis, cerebrovascular disease, arrhythmia and the like.
- Examples 44 and 45 were performed in order to verify the talin activity regulation induced by the compound of
Formula 1 according to the present invention, and as a result, it was shown that the N-acylurea derivative inhibited the activity of talin by binding directly to the talin protein, and thus showed excellent antiplatelet effects. Accordingly, a pharmaceutical composition containing the compound ofFormula 1 or the pharmaceutically acceptable salt thereof according to the present invention can be advantageously used to prevent or treat thrombotic cardiovascular disease by regulating the talin network. - It could be seen that the compound represented by the
Formula 1 of the present invention inhibited angiogenesis through Example 46. -
FIG. 7 shows the antiplatelet mechanism of the novel N-acylurea derivative of the present invention. As reported previously, a talin molecule binds to a GPIIb/IIIa protein, which is present in an inactive state, by a thrombotic signal, thereby causing a morphological change in the GPIIb/IIIa protein and activating the GPIIb/IIIa protein (FIG. 7A ). However, the novel N-acylurea derivative of the present invention binds to the talin molecule, thereby inhibiting the talin molecule from binding directly to the GPIIb/IIIa protein. This maintains the GPIIb/IIIa protein in an inactive state (FIG. 7B ). - Therefore, in still another aspect, the present invention is directed to a method of inhibiting the binding of a talin molecule to a GPIIb/IIIa protein by binding the compound of
Formula 1 to the talin molecule. - The pharmaceutical composition of the present invention may further comprise a suitable carrier, excipient or diluent that is generally used in the preparation of drugs.
- The pharmaceutical composition according to the present invention can be formulated according to a conventional method. For example, it may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, agents for oral and external applications, suppositories, or sterile injection solutions. Carriers, excipients and diluents that can be contained in the composition according to the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
- A pharmaceutical composition according to the present invention is formulated using diluents or excipients, such as fillers, extenders, binders, wetting agents, disintegrants or surfactants, which are commonly used. Solid Formulations for oral administration include tablets, pills, powders, granules, capsules, etc. Such solid Formulations are prepared by mixing the composition of present invention with at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc. In addition to simple expedients, lubricants such as magnesium stearate, talc, etc. may also be added. Liquid Formulations for oral administration, such as suspensions, internal solutions, emulsions, syrups, etc., may include simple diluents, e.g., water and liquid paraffin, as well as various excipients, e.g., wetting agents, sweeteners, aromatics, preservatives, etc. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized agents, suppositories, etc. Non-aqueous solvents and suspensions may be prepared using propylene glycol, polyethylene glycol, vegetable oils such as olive oil, or injectable esters such as ethyloleate. As a base for suppositories, Witepsol, Macrogol, Tween 61, cacao fat, laurin fat, glycerogelatin, etc. may be used.
- The composition of the present invention may be administered orally or parenterally. Any parenteral administration method can be used, and systemic or topical administration can be carried out, but the systemic administration is more preferable and the intravenous administration is most preferable.
- The composition according to the present invention is administered in a pharmaceutically effective amount. As used herein, the term “pharmaceutically effective amount” refers to an amount sufficient to treat the disease at a reasonable benefit/risk ratio applicable for any medical treatment. The effective dosage level of the composition may be determined depending on the type of a patient's disease, the severity of disease, the activity of the drug, sensitivity to the drug, the time of administration, the route of administration and the excretion rate, the duration of treatment, factors including drugs used in combination with the composition, and other factors known in the medical field. The pharmaceutical composition of the present invention may be administered individually or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. The composition can be administered in a single or multiple dosage form. It is important to administer the composition in the minimum amount that can exhibit the maximum effect without causing side effects, in view of all the above-described factors, and this amount can be easily determined by a person skilled in the art.
- More specifically, the effective amount of the compound according to the present invention may vary depending on the patient's age, sex and body weight, and the compound of the present invention may generally be administered at a daily or two-day dose of from 0.1 to 100 mg, preferably from 0.5 to 10 mg per
body weight 1 kg, or may be administered one time to three times per day. However, the dosage may be increased or decreased depending on the route of administration, the severity of the obesity, sex, body weight, age, and thus it is not intended to limit the scope of the present invention in any way. - In yet another aspect, the present invention is directed to a method of preparing the compound of
Formula 1 above, comprising the steps of: (a) mixing and reacting 2-chloroacetamide, N,N-dimethylformamide, potassium carbonate and a nucleophilic reagent in a reactor, terminating the reaction by addition of water, followed by concentration to obtain acetamide; (b) adding oxalyl chloride to the obtained acetamide, replacing the inside of a reactor with argon, and then introducing dichloroethane into the reactor, and heating and stirring, followed by concentration to obtain acetyl isocyanate; and (c) adding methylene chloride to the obtained acetyl isocyanate, adding and reacting a nucleophilic reagent, and terminating the reaction by addition of water, followed by concentration to obtain an N-acylurea derivative. - In one embodiment of the present invention, the obtaining of acetamide in step (a) may comprise dilution with ethyl acetate, washing with water, drying an organic layer with MgSO4, filtration, concentration under reduced pressure, and subjecting the concentrated compound to column chromatography with ethyl acetate/n-hexane.
- In one embodiment of the present invention, the heating in step (a) may be performed at 60-100° C., preferably 75-90° C.
- In one embodiment of the present invention, the obtaining of the N-acylurea derivative in step (c) may comprise diluting the residue, concentrated under reduced pressure, with a suitable solvent, washing with water, collecting an organic layer, drying the organic layer with MgSO4, filtration, concentration under reduced pressure, and subjecting the concentrated compound to column chromatography.
- In a further aspect, the present invention is directed to a method of preparing the compound of
Formula 1 above, comprising the steps of: (a) mixing 2-chloroacetamide with oxalyl chloride in a reactor, replacing the inside of the reactor with argon, introducing dichloroethane into reactor, and heating and stirring, followed by concentration to obtain 2-chloroacetyl isocyanate; (b) adding methylene chloride to the obtained 2-chloroacetyl isocyanate, adding and reacting a nucleophilic reagent, and terminating the reaction by addition of water, followed by concentration to obtain carbamoyl 2-chloroacetamide; and (c) adding methanol to the obtained carbamoyl 2-chloroacetamide, adding and reacting a nucleophilic reagent while stirring, terminating the reaction by addition of water, extracting an N-acylurea derivative with an organic solvent, and then recovering the N-acylurea derivative. - In the present invention, the nucleophilic reagent may be selected from the group consisting of 4-bromo-3-methoxyanilin, 4-methoxybenzylamine, tryptamine, 2,4-dimethoxyaniline, 4-(benzyloxy)aniline, 2-fluoroaniline, Sesamol, 3-fluoropyridin-2-amine, 4-methoxyphenyl)methanamine, 4-(benzyloxy)aniline HCl, 2-Methoxyphenol, 4-phenoxyaniline, 3,5-bis(trifluoromethyl)phenol, 3-bromophenol, 4-bromo-3-methoxyaniline, 2,3-dimethylphenol), and 4-(benzyloxy)phenol.
- In one embodiment of the present invention, the heating in step (a) may be performed at 60-100° C., preferably 75-90° C.
- In one embodiment of the present invention, the obtaining of the 2-chloroacetyl isocyanate in step (b) may comprise diluting the residue, concentrated under reduced pressure, with a solvent, drying an organic layer with MgSO4, filtration, concentration under reduced pressure, and then subjecting the concentrated compound to column chromatography.
- In one embodiment of the present invention, the obtaining of the N-acylurea derivative in step (c) may comprise extracting the residue, concentrated under reduced pressure, with ethyl acetate, drying an organic layer with MgSO4, filtration, concentration under reduced pressure, and then subjecting the concentrated compound to column chromatography.
- Hereinafter, the present invention will be described in further detail with reference to examples. It will be obvious to a person having ordinary skill in the art that these examples are for illustrative purposes only and are not to be construed to limit the scope of the present invention.
-
- Commercially available 2-chloroacetamide (1) was placed in a reactor, and N,N-dimethylformamide was added thereto. Potassium carbonate (3 equivalents) and a nucleophilic reagent (1 equivalent) were added, followed by stirring overnight at a suitable temperature. The reaction was terminated by adding H2O to the reaction solution, followed by concentration under reduced pressure. The residue was diluted with ethyl acetate and washed with water, and the organic layer was dried with MgSO4, filtered, and then concentrated under reduced pressure. The concentrated compound was subjected to column chromatography with ethyl acetate/n-hexane to obtain the desired compound (3).
- The acetamide (3) obtained in
step 1 above and oxalyl chloride (1.5 equivalents) were placed in a reactor, and the inside of the reactor was replaced with argon, after which dichloroethane was introduced into the reactor. The reaction solution was heated to a temperature of 85° C. and stirred for 5 hours. After completion of the reaction, the desired compound (4) was obtained and used in the next reaction without a separate purification procedure. - The acetyl isocyanate obtained in step 2 above was placed in a reactor, and methylene chloride was added thereto, followed by addition of a nucleophilic reagent (5) (1 equivalent). The reaction solution was stirred overnight at room temperature. The reaction was terminated by adding H2O to the reaction solution, followed by concentration under reduced pressure. The residue was diluted with a suitable solvent and washed with water, and then the organic layer was collected. The organic layer was dried with MgSO4, filtered, and then concentrated under reduced pressure. The concentrated compound was subjected to column chromatography to obtain the desired compound (6).
-
- Step 1: Preparation of 2-Chloroacetyl Isocyanate (7) Commercially available 2-chloroacetamide (1) and oxalyl chloride (1.5 equivalents) were placed in a reactor, and the inside of the reactor was replaced with argon, after which dichloroethane was introduced into the reactor. Next, the reaction solution was heated to a temperature of 85° C. and stirred for 5 hours. After completion of the reaction, the reaction solution was concentrated under reduced pressure, and the desired compound (7) was obtained and used in the next step without a separate purification procedure.
- 2-Chloroacetyl isocyanate (7) obtained in
step 1 above was placed in a reactor, and methylene chloride was added thereto, followed by addition of a nucleophilic reagent (5) (1 equivalent). The reaction solution was stirred overnight at room temperature. The reaction solution was terminated by adding H2O to the reaction solution, followed by concentration under reduced pressure. The residue was diluted with a suitable solvent and washed with water, and then the organic layer was collected. The organic layer was dried with MgSO4, filtered, and then concentrated under reduced pressure. The concentrated compound was subjected to column chromatography to obtain the desired compound (8). - The compound carbamoyl 2-chloroacetamide (8)(1 equivalent) obtained in step 2 above was placed in a reactor, and methanol was added thereto, after which a nucleophilic reagent (3 equivalents) was added thereto at 0° C. The solution was stirred for 30 minutes at 0° C., and then stirred overnight at room temperature. The reaction was terminated by addition of H2O, and the reaction solution was extracted with ethyl acetate. The organic layer was dried with MgSO4, filtered, and then concentrated under reduced pressure. The concentrated compound was subjected to column chromatography to obtain the desired compound (6).
-
- The process described in
step 1 of Preparation Example 1 was performed using 5-phenyl-2H-tetrazole as a nucleophilic reagent. - 2-(5-phenyl-2H-tetrazol-2-yl)acetamide (2a)(69 mg, 0.340 mM) obtained in
step 1 above, and oxalyl chloride (1.5 equivalents) (0.049 ml, 0.509 mM) were placed in a reactor, and the inside of the reactor was replaced with argon, after which dichloroethane (1.5 ml) was introduced into the reactor. Next, the reaction solution was heated to a temperature of 85° C., and then stirred for 5 hours. After completion of the reaction, the reaction was concentrated under reduced pressure and used in the next reaction without a separate purification procedure. - 2-(5-phenyl-2H-tetrazol-2-yl)acetyl isocyanate (3a) obtained in step 2 above was placed in a reactor, and methylene chloride (1.7 ml) was added thereto, followed by addition of 4-bromo-3-methoxyaniline (1 equivalent) (68.6 mg, 0.340 mM) as a nucleophilic reagent. The reaction solution was stirred overnight at room temperature. The reaction was terminated by adding H2O to the reaction solution, followed by concentration under reduced pressure. The residue was diluted with ethyl acetate and washed with water, and the organic layer was dried with MgSO4, filtered, and then concentrated under reduced pressure. The concentrated compound was subjected to column chromatography with ethyl acetate:hexane (1:2) to obtain the desired compound (5a) (102 mg, 70%).
- White solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:2); 1H-NMR (DMSO, 500 MHz) δ 8.08 (d, 2H, J=6.0 Hz), 7.61-7.56 (m, 2H), 7.48 (d, 1H, J=5.0 Hz), 7.30 (d, 1H, J=5.0 Hz), 7.16 (dd, 1H, J=2.5 HZ, 2.5 Hz), 5.90 (s, 1H), 3.80 (s, 2H), 3.35 (s, 3H); LC-MS [M+H]+ 432.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 1. - Step 2: This step was performed in the same manner as step 2 of Example 1.
- Step 3: Preparation of N-((4-phenoxyphenyl)carbamoyl)-2-(5-phenyl-2H-tetrazol-2-yl)acetamide (5b)
- This step was performed in the same manner as step 3 of Example 1, except that 4-phenoxyaniline (1 equivalent) (62.9 mg, 0.340 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5b) (91.5 mg, 65%).
- White solid, Rf 0.25 (Ethyl Acetate:n-Hexane=1:2); 1H-NMR (DMSO, 500 MHz) δ 9.94 (s, 1H), 8.085 (dd, 1H, J=1.5 Hz, 9.9 Hz), 7.55 (m, 6.0H), 7.105 (t, 2H, J=7.5 Hz), 6.98 (t, 2H, J=9.0 Hz), 5.89 (s, 1H), 4.03 (q, 2H, J=6.5 Hz); LC-MS [M+H]+ 415.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 1. - Step 2: This step was performed in the same manner as step 2 of Example 1.
- Step 3: This step was performed in the same manner as step 3 of Example 1, except that 4-methoxybenzylamine (1 equivalent) (46.5 mg, 0.340 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5b) (87 mg, 70%).
- White solid, Rf 0.35 (Ethyl Acetate:n-Hexane=1:1); 1H-NMR (DMSO, 500 MHz) δ 8.07 (dd, 2H, J=2.5 Hz, 8.5 Hz), 7.57 (d, 3H, J=6.5 Hz), 7.21 (d, 2H, J=8.5 Hz), 6.88 (d, 2H, J=8.5 Hz), 5.79 (s, 2H), 4.28 (d, 2H, J=6.15 Hz), 3.72 (s, 3H); LC-MS [M+H]+ 367.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 1. - Step 2: This step was performed in the same manner as step 2 of Example 1.
- Step 3: This step was performed in the same manner as step 3 of Example 1, except that tryptamine (1 equivalent) (54.4 mg, 0.340 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5c) (103 mg, 78%).
- Yellow solid, Rf 0.3 (Ethyl Acetate:n-Hexane=2:1); 1H-NMR (DMSO, 500 MHz) δ 10.79 (s, 1H), 8.07 (dd, 1H, J=2.0 Hz, 9.5 Hz), 7.56 (m, 3H), 7.31 (d, 1H, J=8.0 Hz), 7.14 (s, 1H), 7.04 (t, 2H, J=7.0 Hz), 6.95 (t, 2H, J=7.0 Hz), 5.77 (s, 1H), 4.03 (q, 2H, J=7.5 Hz), 3.45 (q, 2H, J=7.0 Hz), 2.87 (t, 2H, J=7.5 Hz); LC-MS [M+Na]+414.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 1. - Step 2: This step was performed in the same manner as step 2 of Example 1.
- Step 3: This step was performed in the same manner as step 3 of Example 1, except that 2,4-dimethoxyaniline (1 equivalent) (52.0 mg, 0.340 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5e) (103 mg, 79%).
- White solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:2); 1H-NMR (DMSO, 500 MHz) M1.24 (s, 1H), 10.15 (s, 1H), 8.10 (dd, 1H, J=2.0 Hz, 9.5 Hz), 7.99 (d, 1H, J=9.0 Hz), 7.59 (d, 3H, J=7.5 Hz), 6.63 (d, 2H, J=2.75 Hz), 6.51 (dd, 1H, J=2.5 Hz, 11.5 Hz), 5.86 (s, 2H), 3.78 (s, 3H), 3.74 (s, 3H); LC-MS [M+Na]+405.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 1. - Step 2: This step was performed in the same manner as step 2 of Example 1.
- Step 3: This step was performed in the same manner as step 3 of Example 1, except that 4-(benzyloxy)aniline (1 equivalent) (116.0 mg, 0.492 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5f) (147 mg, 70%).
- White solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:2); 1H-NMR (DMSO, 500 MHz) δ 11.24 (s, 1H), 9.80 (s, 1H), 8.08 (s, 2H), 7.58 (s, 3H), 7.42-7.32 (m, 4H), 6.97 (s, 2H), 5.89 (s, 2H), 5.07 (s, 2H); LC-MS [M+H]+ 430.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 1. - Step 2: This step was performed in the same manner as step 2 of Example 1.
- Step 3: This step was performed in the same manner as step 3 of Example 1, except that 2-fluoroaniline (1 equivalent) (0.049 mg, 0.51 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5g) (121 mg, 70%).
- White solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:2); 1H-NMR (DMSO, 500 MHz) δ 10.18 (s, 1H), 8.11-8.08 (m, 3H), 7.60-7.56 (m, 3H), 7.30-7.13 (m, 3H), 5.90 (s, 2H); LC-MS [M+H]+ 341.
-
- Step 1: The process described in
step 1 of Preparation Example 1 was performed using sesamol as a nucleophilic reagent. - Step 2: This step was performed in the same manner as step 2 of Example 1, except that 2-(benzo[d][1,3]dioxol-5-yloxy)acetamide (2i) (60 mg, 0.335 mM) was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetamide (2a).
- Step 3: This step was performed in the same manner as step 3 of Example 1, except that 2-(benzo[d][1,3]dioxol-5-yloxy)acetyl isocyanate (3i) obtained in step 2 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetyl isocyanate (3a), and 3-fluoropyridin-2-amine (1 equivalent) (38.7 mg, 0.345 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5i) (90.8 mg, 79%).
- Yellow solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:2); 1H-NMR (DMSO, 500 MHz) δ 10.34 (s, 1H), 8.43 (s, 1H), 7.215 (d. 1H, J=8.5 Hz), 6.890-6.790 (m, 3H), 6.6395 (s, 1H), 6.33 (d, 1H, J=8.75), 4.64 (s, 2H), 4.30 (dd, 1H, J=5.5 Hz); LC-MS [M+Na]+357.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 8. - Step 2: This step was performed in the same manner as step 2 of Example 8.
- Step 3: This step was performed in the same manner as step 3 of Example 8, except that 4-bromo-3-methoxyaniline (69.8 mg, 0.345 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5j) (96 mg, 66%).
- Yellow solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:2); 1H-NMR (DMSO, 500 MHz) δ 10.69 (s, 1H), 10.26 (s, 1H), 7.49 (d, 1H, J=8.5 Hz), 7.31 (s, 1H), 7.14 (d, 1H, J=9.0 Hz), 6.82 (d, 1H, J=8.25 Hz), 6.68 (s, 1H), 6.38 (d, 1H, J=8.75 Hz), 5.97 (s, 2H), 4.75 (s, 2H), 3.83 (s, 3H); LC-MS [M+Na]+446.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 8. - Step 2: This step was performed in the same manner as step 2 of Example 8.
- Step 3: This step was performed in the same manner as step 3 of Example 8, except that 4-phenoxyaniline (64 mg, 0.345 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5k) (98 mg, 70%).
- Gray solid, Rf 0.4 (Ethyl Acetate:n-Hexane=1:3); 1H-NMR (DMSO, 500 MHz) δ 10.63 (s, 1H), 10.18 (s, 1H), 7.53 (d, 2H, J=8.5 Hz), 7.37 (t, 2H, J=8.5 Hz), 7.158 (t, 4H, J=7.0 Hz), 6.82 (d, 1H, J=8.5 Hz), 6.68 (s, 1H), 6.38 (dd, 1H, J=2.5 Hz, 11 Hz), 5.97 (s, 2H), 4.73 (s, 2H); LC-MS [M+H]+ 408.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 8. - Step 2: This step was performed in the same manner as step 2 of Example 8.
- Step 3: This step was performed in the same manner as step 3 of Example 8, except that (4-methoxyphenyl) methanamine (47.4 mg, 0.345 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5l) (86.5 mg, 70%).
- Yellow solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:2); 1H-NMR (DMSO, 500 MHz) δ 11.13 (s, 1H), 10.23 (s, 1H), 8.227 (d, 1H, J=4.5 Hz), 7.8 (t, 1H, J=9.8 Hz), 7.345-7.31 (m, 2H), 6.82 (d, 1H, J=8.0 Hz), 6.69 (s, 1H), 5.97 (s, 2H), 4.77 (s, 2H), 1.24 (s, 2H); LC-MS [M+Na]+382.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 8. - Step 2: This step was performed in the same manner as step 2 of Example 8.
- Step 3: This step was performed in the same manner as step 3 of Example 8, except that tryptamine (55.3 mg, 0.345 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5m) (92 mg, 70%).
- Yellow solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:2); 1H-NMR (DMSO, 500 MHz) δ 10.81 (s, 1H), 10.26 (s, 1H), 7.56 (d, 1H, J=7.5 Hz), 7.33 (d, 1H, J=8.0 Hz), 7.15 (s, 1H), 7.06 (t, 1H, J=7.5 Hz), 6.96 (t, 1H, J=7.0 Hz), 6.80 (d, 1H, J=8.5 Hz), 6.64 (d, 1H, J=2.5 Hz), 6.33 (dd, 1H, J=2.5 Hz, 11.0 Hz), 5.96 (s, 2H), 4.61 (s, 2H), 3.46 (q, 2H, J=7.4 Hz), 2.88 (t, 2H, J=7.0 Hz).
-
- Step 1: This step was performed in the same manner as
step 1 of Example 8. - Step 2: This step was performed in the same manner as step 2 of Example 8.
- Step 3: This step was performed in the same manner as step 3 of Example 8, except that 2,4-dimethoxyaniline (52.9 mg, 0.345 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5n) (90 mg, 70%).
- Brown solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:2); 1H-NMR (DMSO, 500 MHz) δ 10.66 (s, 1H), 10.39 (s, 1H), 7.99 (d, 1H, J=8.8 Hz), 6.83-6.80 (m, 1H), 6.65 (dd, 2H, J=2.5 Hz, 17.2 Hz), 6.50 (dd, 1H, J=2.5 Hz, 11.3 Hz), 6.36 (dd, 1H, J=2.5 Hz, 11.0 Hz), 5.97 (d, 2H, J=5.3 Hz), 4.70 (s, 2H), 3.83 (s, 3H), 3.74 (s, 3H); LC-MS [M+H]+ 375.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 8. - Step 2: This step was performed in the same manner as step 2 of Example 8.
- Step 3: This step was performed in the same manner as step 3 of Example 8, except that 4-(benzyloxy)aniline HCl (81.4 mg, 0.345 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (50) (60.9 mg, 42%).
- Brown solid, Rf 0.35 (Ethyl Acetate:n-Hexane=1:2); 1H-NMR (DMSO, 500 MHz) δ 10.59 (s, 1H), 10.04 (s, 1H), 7.45-7.31 (m, 6H), 6.98 (d, 2H, J=9.3 Hz), 6.82 (d, 1H, J=8.3 Hz), 6.68 (d, 1H, J=2.5 Hz), 6.37 (dd, 1H, J=2.5 Hz, 11.0 Hz), 5.97 (s, 2H), 5.08 (s, 2H), 4.72 (s, 2H); LC-MS [M+H]+ 421.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 8. - Step 2: This step was performed in the same manner as step 2 of Example 8.
- Step 3: This step was performed in the same manner as step 3 of Example 8, except that 2-fluoroaniline (0.033 ml, 0.345 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5p) (43.5 mg, 38%).
- White solid, Rf 0.35 (Ethyl Acetate:n-Hexane=1:3); 1H-NMR (DMSO, 500 MHz) δ 10.89 (s, 1H), 10.48 (s, 1H), 8.13 (t, 1H, J=7.6 Hz), 7.29 (t, 1H, J=10.1 Hz), 7.21-7.11 (m, 2H), 6.82 (d, 1H, J=8.5 Hz), 6.69 (d, 1H, J=6.3 Hz), 6.38 (dd, 1H, J=2.5 Hz, 11.0 Hz), 5.97 (s, 2H), 4.74 (s, 2H); LC-MS [M+H]+ 333.
-
- Step 1: The process described in
step 1 of Preparation Example 1 was performed using 2-Methoxyphenol as a nucleophilic reagent. - Step 2: This step was performed in the same manner as step 2 of Example 1, except that 2-(2-methoxyphenoxy) acetamide (2q) (40 mg, 0.2207 mM) was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetamide (2a).
- Step 3: This step was performed in the same manner as step 3 of Example 1, except that 2-(2-methoxyphenoxy)acetyl isocyanate (3q) obtained in step 2 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetyl isocyanate (3a), and 3-fluoropyridin-2-amine (1 equivalent) (24.7 mg, 0.221 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5q) (17 mg, 24%).
- White solid, Rf 0.4 (Ethyl Acetate:n-Hexane=1:1); 1H-NMR (DMSO, 500 MHz) δ 11.08 (s, 1H), 10.22 (s, 1H), 8.21 (s, 1H), 7.79 (t, 1H, J=9.5 Hz), 7.33 (m, 2H), 6.95 (m, 2H), 4.83 (s, 2H), 3.79 (s, 3H); LC-MS [M+Na]+343.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 16. - Step 2: This step was performed in the same manner as step 2 of Example 16.
- Step 3: This step was performed in the same manner as step 3 of Example 16, except that 4-bromo-3-methoxyaniline (44.6 mg, 0.221 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5r) (63 mg, 70%).
- White solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:3); 1H-NMR (DMSO, 500 MHz) δ 10.72 (s, 1H), 10.31 (s, 1H), 7.49 (d, 1H, J=7.5 Hz), 7.31 (s, 1H), 7.16 (d, 1H, J=9.0 Hz), 7.01 (d, 1H, J=7.5 Hz), 6.96-6.85 (m, 3H), 4.81 (s, 2H), 3.82 (s, 3H), 3.78 (s, 3H); LC-MS [M+Na]+431.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 16. - Step 2: This step was performed in the same manner as step 2 of Example 16.
- Step 3: This step was performed in the same manner as step 3 of Example 15, except that 4-phenoxyaniline (51.1 mg, 0.276 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5s) (62 mg, 57%).
- Yellow solid, Rf 0.32 (Ethyl Acetate:n-Hexane=1:3); 1H-NMR (DMSO, 500 MHz) δ 10.58 (s, 1H), 10.16 (s, 1H), 7.54 (d, 2H, J=10.0 Hz), 7.37 (t, 2H, J=8.0 Hz), 7.12 (t, 2H, J=7.5 Hz), 7.02-6.86 (m, 7H), 4.80 (s, 2H), 3.80 (s, 3H); LC-MS [M+H]+ 393.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 16. - Step 2: This step was performed in the same manner as step 2 of Example 16.
- Step 3: This step was performed in the same manner as step 3 of Example 16, except that 4-methoxyphenyl)methanamine (0.029 ml, 0.221 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5t) (31 mg, 41%).
- White solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:2); 1H-NMR (DMSO, 500 MHz) δ 10.25 (s, 1H), 8.44 (s, 1H), 7.22 (d, 3H=7.5 Hz), 7.01-6.84 (m, 5H), 4.70 (s, 2H), 4.30 (s, 3H), 3.77 (s, 3H), 3.73 (s, 3H); LC-MS [M+H]+ 345.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 16. - Step 2: This step was performed in the same manner as step 2 of Example 16.
- Step 3: This step was performed in the same manner as step 3 of Example 16, except that tryptamine (53 mg, 0.331 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5u) (94.6 mg, 76%).
- White solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:2); 1H-NMR (DMSO, 500 MHz) δ 10.82 (s, 1H), 10.20 (s, 1H), 7.56 (d, 1H, J=7.8 Hz), 7.33 (s, 1H), 7.16 (s, 1H), 7.08-6.86 (m, 5H), 4.68 (s, 2H), 3.78 (s, 2H), 3.46 (q, 2H, J=7.5 Hz), 3.32 (s, 3H), 2.88 (t, 2H, J=7.0 Hz); LC-MS [M+H]+ 369.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 16. - Step 2: This step was performed in the same manner as step 2 of Example 16.
- Step 3: This step was performed in the same manner as step 3 of Example 16, except that 2,4-dimethoxyaniline (51 mg, 0.331 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5v) (83.4 mg, 70%).
- Brown solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:5); 1H-NMR (DMSO, 500 MHz) δ 10.61 (s, 1H), 10.39 (s, 1H), 7.99 (d, 1H, J=8.8 Hz), 7.02 (d, 1H, J=8.0 Hz), 6.97-6.86 (m, 4H), 6.65 (d, 1H, J=2.5 Hz), 6.51 (dd, 1H, J=2.5 Hz, 11.4 Hz), 4.77 (s, 2H), 3.83 (s, 2H), 3.80 (s, 3H), 3.74 (s, 3H); LC-MS [M+H]+ 361.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 16. - Step 2: This step was performed in the same manner as step 2 of Example 16.
- Step 3: This step was performed in the same manner as step 3 of Example 16, except that 4-(benzyloxy)aniline (52 mg, 0.221 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5w) (56.5 mg, 63%).
- Brown solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:3); 1H-NMR (DMSO, 500 MHz) δ 10.58 (s, 1H), 10.06 (s, 1H), 7.53-6.88 (m, 13H), 5.07 (s, 2H), 4.78 (s, 2H), 3.79 (s, 3H); LC-MS [M+Na]+430.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 16. - Step 2: This step was performed in the same manner as step 2 of Example 16.
- Step 3: This step was performed in the same manner as step 3 of Example 16, except that 2-fluoroaniline (0.033 ml, 0.331 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5x) (74 mg, 70%).
- White solid, Rf 0.4 (Ethyl Acetate:n-Hexane=1:4); 1H-NMR (DMSO, 500 MHz) δ 10.86 (s, 1H), 10.48 (s, 1H), 8.13 (t, 1H, J=8.0 Hz), 7.3 (t, 1H, J=8.0 Hz), 7.21-7.11 (m, 2H), 7.03-6.86 (m, 4H), 4.81 (s, 2H), 3.80 (s, 3H); LC-MS [M+H]+ 319.
-
- Step 1: The process described in
step 1 of Preparation Example 1 was performed using 3,5-bis(trifluoromethyl)phenol as a nucleophilic reagent. - Step 2: This step was performed in the same manner as step 2 of Example 1, except that 2-(3,5-bis(trifluoromethyl)phenoxy)acetamide (2y) (70 mg, 0.244 mM) obtained in
step 1 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetamide (2a). - Step 3: This step was performed in the same manner as step 3 of Example 1, except that 2-(3,5-bis(trifluoromethyl)phenoxy)acetyl isocyanate (3y) obtained in step 2 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetyl isocyanate (3a), and 3-fluoropyridin-2-amine (1 equivalent) (27 mg, 0.243 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5y) (72 mg, 70%).
- White solid, Rf 0.4 (Ethyl Acetate:n-Hexane=1:4); 1H-NMR (DMSO, 500 MHz) δ 11.23 (s, 1H), 10.17 (s, 1H), 8.24 (s, 1H), 7.81-7.68 (m, 4H), 7.34 (s, 1H), 5.16 (s, 2H); LC-MS [M+H]+ 427.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 24. - Step 2: This step was performed in the same manner as step 2 of Example 24.
- Step 3: This step was performed in the same manner as step 3 of Example 24, except that 4-bromo-3-methoxyaniline (52.5 mg, 0.259 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5z) (29 mg, 22%).
- Yellow solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:4); 1H-NMR (DMSO, 500 MHz) δ 10.75 (s, 1H), 10.15 (s, 1H), 7.72 (s, 1H), 7.68 (s, 1H), 7.5 (d, 2H, J=8.8 Hz), 7.3 (d, 1H, J=2.5 Hz), 7.2 (dd, 1H, J=2.3 Hz, 11.0 Hz), 3.82 (s, 2H), 3.2 (d, 3H, J=5.0 Hz).
-
- Step 1: This step was performed in the same manner as
step 1 of Example 24. - Step 2: This step was performed in the same manner as step 2 of Example 24.
- Step 3: This step was performed in the same manner as step 3 of Example 24, except that 4-phenoxyaniline (45.0 mg, 0.243 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5aa) (98 mg, 81%).
- White solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:5); 1H-NMR (DMSO, 500 MHz) δ 10.71 (s, 1H), 10.06 (s, 1H), 7.7 (d, 3H, J=22.5 Hz), 7.54 (s, 2H), 7.37 (s, 2H), 7.11 (s, 1H), 7.0 (s, 4H), 5.11 (s, 2H); LC-MS [M+Na]+521.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 24. - Step 2: This step was performed in the same manner as step 2 of Example 24.
- Step 3: This step was performed in the same manner as step 3 of Example 24, except that 4-methoxyphenyl)methanamine (0.031 8 ml, 0.243 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5ab) (66.7 mg, 61%).
- White solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:3); 1H-NMR (DMSO, 500 MHz) δ 10.47 (s, 1H), 8.40 (s, 1H), 7.68-7.64 (m, 3H), 7.22-7.16 (m, 2H), 6.88-6.84 (m, 2H), 5.00 (s, 2H), 4.29 (d, 2H, J=5.8 Hz), 3.72 (s, 3H); LC-MS [M+Na]+473.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 24. - Step 2: This step was performed in the same manner as step 2 of Example 24.
- Step 3: This step was performed in the same manner as step 3 of Example 24, except that tryptamine (33.5 mg, 0.209 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5ac) (69 mg, 70%).
- White solid, Rf 0.2 (Ethyl Acetate:n-Hexane=1:2); 1H-NMR (DMSO, 500 MHz) δ 10.81 (s, 1H), 10.40 (s, 1H), 8.14 (s, 1H), 7.68 (d, 2H, J=5.5 Hz), 7.56 (d, 1H, J=8.0 Hz), 7.33 (d, 1H, J=8.3 Hz), 7.15 (d, 1H, J=2.5 Hz), 7.05 (t, 1H, J=7.5 Hz), 6.96 (t, 1H, J=7.5 Hz), 4.98 (s, 2H), 3.46 (q, 2H, J=7.4 Hz), 2.88 (t, 2H, J=7.3 Hz); LC-MS [M+H]+ 475.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 24. - Step 2: This step was performed in the same manner as step 2 of Example 24.
- Step 3: This step was performed in the same manner as step 3 of Example 24, except that 2,4-dimethoxyaniline (40 mg, 0.261 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5ad) (60 mg, 49%).
- Brown solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:4); 1H-NMR (DMSO, 500 MHz) δ 10.76 (s, 1H), 8.0 (d, 1H, J=8.7 Hz), 7.7 (d, 1H J=15.0 Hz), 6.6 (d, 1H, J=2.5 Hz), 6.58 (d, 1H, J=7.8 Hz), 6.6 (dd, 1H, J=2.5 Hz, 11.0 Hz), 6.5 (d, 1H, J=2.5 Hz), 3.74 (s, 3H), 3.65 (s, 3H); LC-MS [M+H]+ 467.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 24. - Step 2: This step was performed in the same manner as step 2 of Example 24.
- Step 3: This step was performed in the same manner as step 3 of Example 24, except that 4-(benzyloxy)aniline HCl (61 mg, 0.260 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5ae) (32 mg, 24%).
- Brown solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:4); 1H-NMR (DMSO, 500 MHz) δ 10.65 (s, 1H), 9.93 (s, 1H), 7.72 (s, 2H), 7.68 (s, 1H), 7.44-7.37 (m, 5H), 7.33-7.30 (m, 2H), 5.1 (d, 2H, J=7.0 Hz), 3.2 (d, 2H); LC-MS [M+Na]+536.
-
- Step 1: This step was performed in the same manner as
step 1 of Example 24. - Step 2: This step was performed in the same manner as step 2 of Example 24.
- Step 3: This step was performed in the same manner as step 3 of Example 24, except that 2-fluoroaniline (0.025 ml, 0.260 mM) was used instead of 3-fluoropyridin-2-amine as the nucleophilic reagent, thereby obtaining the desired compound (5af) (84 mg, 76%).
- White solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:4); 1H-NMR (DMSO, 500 MHz) δ 10.96 (s, 1H), 10.36 (s, 1H), 8.20 (t, 1H, J=9.8 Hz), 7.73 (s, 2H), 7.69 (s, 1H), 7.33 (t, 1H, J=9.8 Hz), 7.2 (t, 1H, J=7.6 Hz), 7.15-7.11 (m, 1H), 5.10 (s, 2H); LC-MS [M+Na]+447.
-
- Step 1: The process described in
step 1 of Preparation Example 1 was performed using 3-bromophenol as a nucleophilic reagent. - Step 2: This step was performed in the same manner as step 2 of Example 1, except that 2-(3-bromophenoxy)acetamide (2ag) (36 mg, 0.158 mM) obtained in
step 1 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetamide (2a). - Step 3: This step was performed in the same manner as step 3 of Example 1, except that 2-(3-bromophenoxy)acetyl isocyanate (3ag) obtained in step 2 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetyl isocyanate (3a), and 4-bromo-3-methoxyaniline (1 equivalent) (27 mg, 0.243 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5ag) (84 mg, 76%).
- White solid, Rf 0.4 (Ethyl Acetate:n-Hexane=1:4); 1H-NMR (DMSO, 500 MHz) δ 10.73 (s, 1H), 10.34 (s, 1H), 7.98 (d, 1H, J=9.3 Hz), 7.29-7.16 (m, 3H), 6.98 (dd, 1H, J=1.5 Hz, 10.0 Hz), 6.64 (d, 1H, J=3.0 Hz), 6.50 (dd, 1H, J=2.3 Hz, 11.0 Hz), 4.83 (s, 2H), 3.82 (s, 3H).
-
- Step 1: This step was performed in the same manner as
step 1 of Example 32. - Step 2: This step was performed in the same manner as step 2 of Example 32.
- Step 3: This step was performed in the same manner as step 3 of Example 32, except that 2,4-dimethoxyaniline (1 equivalent) (0.025 ml, 0.260 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5ah) (52 mg, 49%).
- Yellow solid, Rf 0.25 (Ethyl Acetate:n-Hexane=1:4); 1H-NMR (DMSO, 500 MHz) δ 10.19 (s, 1H), 7.5 (d, 2H, J=8.5 Hz), 7.30-7.17 (m, 4H), 7.0 (dd, 1H, J=2.3 Hz, 10.5 Hz), 5.75 (s, 2H), 3.81 (s, 3H); LC-MS [M+H]+ 409.
-
- The process described in
step 1 of Preparation Example 1 was performed using 2,3-dimethylphenol as a nucleophilic reagent. - This step was performed in the same manner as step 2 of Example 1, except that 2-(3,5-dimethylphenoxy)acetamide (2aj) (50 mg, 0.279 mM) obtained in
step 1 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetamide (2a). - This step was performed in the same manner as step 3 of Example 1, except that 2-(2,3-dimethylphenoxy)acetyl isocyanate) (3aj) obtained in step 2 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetyl isocyanate (3a), and 2-fluoroaniline (1 equivalent) (0.0224 ml, 0.233 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5aj) (44.2 mg, 50%).
- White solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:4); 1H-NMR (DMSO, 500 MHz) δ 10.95 (s, 1H), 10.49 (s, 1H), 8.12 (t, 1H, J=9.7 Hz), 7.30 (m, 1H), 7.20 (t, 1H, J=7.0 Hz), 7.13 (m, 1H), 7.03 (t, 1H, J=8.0 Hz), 6.80 (d, 1H, J=7.7 Hz, 6.68 (d, 1H, J=8.3 Hz), 4.82 (s, 2H), 2.23 (s, 3H), 2.14 (s, 3H).
-
- The process described in
step 1 of Preparation Example 1 was performed using 4-(benzyloxy)phenol as a nucleophilic reagent. - This step was performed in the same manner as step 2 of Example 1, except that 2-(4-(benzyloxy)phenoxy)acetamide (2ak) (50 mg, 0.194 mM) obtained in
step 1 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetamide (2a). - This step was performed in the same manner as step 3 of Example 1, except that 2-(4-(benzyloxy)phenoxy)acetyl isocyanate (3ak) obtained in step 2 was used instead of 2-(5-phenyl-2H-tetrazol-2-yl)acetyl isocyanate (3a), and 2-fluoroaniline (1 equivalent) (0.0156 ml, 0.162 mM) was used instead of 4-bromo-3-methoxyaniline as the nucleophilic reagent, thereby obtaining the desired compound (5ak) (27.6 mg, 36%).
- White solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:3); 1H-NMR (DMSO, 500 MHz) δ 10.92 (s, 1H), 10.50 (s, 1H), 8.13 (t, 1H, J=8.3 Hz), 7.43 (d, 2H), 7.38 (t, 2H, J=7.3 Hz), 7.33-7.28 (m, 2H), 7.20 (t, 1H, J=7.3 Hz), 7.13 (m, 1H), 6.96-6.94 (m, 2H), 6.91-6.89 (m, 2H), 5.04 (s, 2H), 4.75 (s, 2H).
-
- Step 1: This step was performed in the same manner as
step 1 of Example 33. - Step 2: This step was performed in the same manner as step 2 of Example 33.
- Step 3: Preparation of tert-butyl 4-(2-(3-(2-fluorophenyl)ureido)-2-oxoethyl)piperazine-1-carboxylate
- Tert-butyl piperazine-1-carboxylate (1 equivalent)(162 mg, 0.867 mM) was added to the compound (2-chloro-N-((2-fluorophenyl)carbamoyl)acetamide)(1 equivalent)(200 mg, 0.867 mM) obtained in step 2, and then the reactor was set to 80° C., after which methanol (6 ml) was added and the solution was stirred for 4 hours. The reaction was terminated by addition of H2O to the reaction solution, and the reaction solution was extracted with ethyl acetate. The organic layer was dried with MgSO4, filtered, and then concentrated under reduced pressure. The concentrated compound was subjected to column chromatography with Ethyl acetate:Hexane (1:1) to obtain the desired compound tert-butyl 4-(2-(3-(2-fluorophenyl)ureido)-2-oxoethyl) piperazine-1-carboxylate (122 mg, 37%).
- Yellow solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:2); 1H-NMR (CDCl3, 500 MHz) δ 10.57 (s, 1H), 9.26 (s, 1H), 8.19 (t, 1H, J=7.5 Hz), 7.15-7.05 (m, 3H), 3.53 (s, 4H), 3.23 (s, 2H), 2.58 (s, 4H), 1.48 (s, 6H).
-
- Step 1: The process described in
step 1 of Preparation Example 2 was performed. - Step 2: The process described in step 2 of Preparation Example 2 was performed using 2-Fluoroaniline as a nucleophilic reagent.
- Step 3: Methanol (4 ml) was added to the compound (2-chloro-N-((2-fluorophenyl)carbamoyl)acetamide)(1 equivalent)(191 mg, 0.830 mM) obtained in step 2, and then the reactor was set to 80° C., after which morpholine (3 equivalents) (217 mg, 2.49 mM) was added and the solution was stirred for 30 minutes. The reaction solution was stirred overnight at room temperature. The reaction was terminated by addition of H2O to the reaction solution, and the reaction solution was extracted with ethyl acetate. The organic layer was dried with MgSO4, filtered, and then concentrated under reduced pressure. The concentrated compound was subjected to column chromatography with Ethyl acetate:Hexane (1:2) to obtain the desired compound N-((2-fluorophenyl)carbamoyl)-2-morpholinoacetamide)(124 mg, 53%).
- White solid, Rf 0.3 (Ethyl Acetate:n-Hexane=1:2); 1H-NMR (CDCl3, 500 MHz) δ 10.59 (s, 1H), 9.25 (s, 1H), 8.20 (t, 1H, J=7.6 Hz), 7.16-7.05 (m, 3H), 3.79 (t, 4H, J=4.5 Hz), 3.20 (s, 2H), 2.62 (t, 4H, J=4.8 Hz).
- <Example 38> Screening of Talin Antagonist Candidates Platelets bind to fibrinogen present in blood and produce thrombi. This binding is mediated by integrin αEIIbβ3 present in the platelet cell membrane, and this integrin binds to fibrinogen after being activated by talin. In order to enable high-throughput efficacy testing by simplifying this procedure into a cell line-based experiment, integrin αEIIbβ3 was first stably expressed in the CHO cell line using lentivirus, thereby constructing a CHO/αEIIbβ3 cell line. The constructed cell line was cultured in a fibrinogen-coated 96-well plate for 1 hour and washed, after which the amount of remaining cells was measured to evaluate the efficacy of a talin antagonist candidate. In this procedure, in order to measure the relative amount of the CHO/αEIIbβ3 cell line remaining in the well due to binding to fibrinogen, a cell counting kit-8 (CCK-8) was used to measure the activity of dehydrogenase present in the remaining cells. When the activity of dehydrogenase appeared due to the presence of the cells, the color of CCK-8 changed from yellow to orange (
FIG. 1 ). To measure the degree to which the color changed to orange, the absorbance at a wavelength of 450 nm was measured with a plate reader. This enabled easy, fast and reliable high-throughput screening. - To screen talin antagonist candidates, inhibition of the binding affinity between the CHO/αEIIbβ3 cell line and fibrinogen was examined by the above-described efficacy testing method.
- As a result, it was shown that compounds, including KCH-1420, KCH-1424, KCH-1510, KCH-1511, KCH-1512, KCH-1513, KCH-1516, KCH-1518, KCH-1521, KCH-1523, KCH-1526, KCH-1529, KCH-1530, and KCH-1542 inhibited the binding between the CHO/αEIIbβ3 cell line and fibrinogen by at least 80% compared to a negative control (
FIG. 2 ).FIG. 3 shows the concentration-dependent effects of KCH-1513 and KCH-1521 on inhibition of the binding between the CHO/αEIIbβ3 cell line and fibrinogen. InFIG. 3 , likeFIG. 2 , cells expressing platelet integrin αEIIbβ3 were incubated with varying concentrations of a candidate, and the binding between the cells and fibrinogen was examined. Cell adhesion on the Y-axis is the relative degree of cell-fibrinogen binding. KCH-1513 and KCH-1521 showed an inhibitory effect of at least 50% at a concentration ranging from 0.02 to 0.07 mM. - To measure the binding affinity between the talin protein and a talin antagonist candidate, surface plasmon resonance spectroscopy was used. Specifically, a talin antagonist candidate was added to the talin protein immobilized on a sensor chip, and the affinity constant between the two substances was measured by surface plasmon resonance (hereinafter referred to as ‘SPR’) spectrometry.
- Talin is divided into an N-terminal head domain and a C-terminal rod domain, and the head domain is further divided into four subdomains, F0, F1, F2 and F3. Among them, F3 is known as an integrin binding site. Thus, 6×His-tagged F2F3 protein containing F3 was isolated and purified. As a sensor chip for immobilizing the talin protein, HTEPBE10PO1 (Biorad) was used. SPR was measured using ProteON™ XPR36 (Biorad).
- As a result, as shown in
FIG. 4 , the compounds KCH-1513 and KCH-1521 were measured to have affinity constants of 9.33×10−3 M and 2.71×10−4 M, respectively, and it was shown that the talin antagonist candidates did bind to the talin protein in a concentration-dependent manner. - In order to examine whether platelet aggregation is actually inhibited by the compound KCH-1513 or KCH-1521, this test was performed. It is well known that platelets bind to fibrinogen in blood and form thrombi, which leads to the contraction of intracellular skeletal muscle due to signaling after the binding between activated integrin αEIIbβ3 and fibrinogen. To achieve this thrombus formation in vitro, mouse blood platelets were isolated and thrombin known as a platelet activator was added thereto. As a result, as shown in the left photograph of
FIG. 5 , the platelets were aggregated. However, when platelets were treated with thrombin in combination with KCH-1513 or KCH-1521, it was observed that platelet aggregation that was increased by thrombin decreased when 0.2 mM of KCH-1513 (middle photograph) or the same concentration of KCH-1521 (right photograph) was added. This suggests that the KCH-1513 and KCH-1521 compounds of the present invention significantly inhibit platelet aggregation as shown inFIG. 5 . - Platelets isolated from human peripheral blood were treated with TRAP (32 μM), ADP (6.5 μM) and arachidonic acid (AA; 0.5 mM), which are platelet aggregation agonists, in combination with different concentrations (0 μM, 10 μM and 30 μM) of various compounds (KCH-1513 and KCH-1521), and inhibition of aggregation of the platelets was compared (
FIG. 6 ). As a result, it could be seen that KCH-1513 and KCH-1521 had platelet aggregation inhibitory activities similar to that of a positive control. - Platelets isolated from human peripheral blood, which has been administered with conventional platelet inhibitors (cyclooxygenase inhibitor and ADP receptor blocker), were treated with ADP (6.5 μM), TRAP (32 μM) and arachidonic acid (AA; 0.5 mM), which are platelet aggregation agonists, in combination with KCH-1526, and inhibition of aggregation of the platelets was compared (
FIG. 8 ). As a result, it could be seen that treatment with the representative novel compound KCH-1526 exhibited similar or better platelet aggregation inhibitory activity than those of the conventional platelet inhibitors (cyclooxygenase inhibitor and ADP receptor blocker) in the platelets treated with the platelet aggregation agonists (ADP, TRAP and arachidonic acid). - Hereinafter, formulations which may be prepared as pharmaceutical compositions of the present invention will be illustrated.
- 1. Preparation of Powder Formulation
- N-acylurea derivative: 2 g;
- Lactose: 1 g
- The above components were mixed with each other and filled into an airtight bag, thereby preparing a powder formulation.
- 2. Preparation of Tablet Formulation
- N-acylurea derivative: 100 mg;
- Corn starch: 100 mg;
- Lactose: 100 mg;
- Magnesium stearate: 2 mg.
- The above components were mixed with one another and compressed into a tablet according to a conventional tablet preparation method, thereby preparing a tablet formulation.
- 3. Preparation of Capsule Formulation
- N-acylurea derivative: 100 mg;
- Corn starch: 100 mg;
- Lactose: 100 mg;
- Magnesium stearate: 2 mg.
- The above components were mixed with one another and filled into a gelatin capsule according to a conventional capsule preparation method, thereby preparing a capsule formulation.
- 4. Preparation of Injectable Formulation
- N-acylurea: 10 μg/ml;
- Dilute hydrochloric acid BP: to pH 3.5;
- Sodium chloride BP for injection: to 1 ml.
- A 2-ethoxypropionic acid derivative was dissolved in a suitable volume of sodium chloride BP for injection, the pH of the resultant solution was adjusted to pH3.5 with dilute hydrochloric acid BP, and then the solution was made to volume with sodium chloride BP for injection and thoroughly mixed. The solution was filled into 5 ml type I clear glass ampoules which were then sealed under a headspace of air by fusion of the glass, and then sterilized by autoclaving at 120° C. for not less than 15 minutes, thereby preparing an injectable liquid formulation.
- The N-acylurea derivative according to the present invention can inhibit platelet aggregation by inhibiting the activity of talin in the intracellular matrix, and thus can be useful for the prevention or treatment of cardiovascular disease.
- Although the present invention has been described in detail with reference to the specific features, it will be apparent to those skilled in the art that this description is only for a preferred embodiment and does not limit the scope of the present invention. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof
Claims (12)
1. A compound represented by Formula 1 or a pharmaceutically acceptable salt thereof:
wherein
R1 is tetrazolyl, piperazinyl, morpholinyl, phenyl linked by O, or benzodioxolyl linked by O, wherein the tetrazolyl, piperazinyl, morpholinyl, phenyl, or benzodioxolyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of halogen, C1-6 haloalkyl, C1-6 alkoxy, phenyl, phenoxy, and —O—C2-20 alkylene-phenyl;
R2 is phenyl, pyridinyl, C2-20 alkylene-phenyl, C2-20 alkylene-indolyl, or C2-20 alkylene-dihydroindolyl, wherein the phenyl, pyridinyl, indolyl, or dihydroindolyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, —C1-6 alkoxy-C1-6 alkyl, —O-phenyl, and —O—C2-20 alkylene-phenyl; and
R3 and R4 are each independently hydrogen, C1-6 alkyl or C1-6 haloalkyl.
2. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein R1 is tetrazolyl, phenyl linked by O or benzodioxolyl linked by O, wherein the tetrazolyl, phenyl or benzodioxolyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of halogen, C1-6 haloalkyl, C1-6 alkoxy, phenyl, phenoxy, and —O—C2-20 alkylene-phenyl.
3. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the tetrazolyl, phenyl linked by O or benzodioxolyl linked by O in R1 is substituted with 1 to 3 substituents selected from the group consisting of halogen, C1-6 alkoxy, phenyl and phenoxy.
4. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein R2 is phenyl, C2-20 alkylene-indolyl or C2-20 alkylene-dihydroindolyl, wherein the phenyl, indolyl, or dihydroindolyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, —C1-6 alkoxy-C1-6 alkyl, —O-phenyl, and —O—C2-20 alkylene-phenyl.
5. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the phenyl, pyridinyl, indolyl, or dihydroindolyl in R2 is substituted with 1 to 3 substituents selected from the group consisting of halogen, C1-6 alkoxy, phenoxy, and —O—C2-20 alkylene-phenyl.
6. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein R3 and R4 are each independently hydrogen.
7. A pharmaceutical composition for treating cardiovascular disease, comprising the compound or the pharmaceutically acceptable salt thereof of claim 1 , as an active ingredient, and a pharmaceutically acceptable carrier.
8. The pharmaceutical composition of claim 7 , wherein the cardiovascular disease is selected from the group consisting of hypertension, ischemic heart disease, coronary artery disease, angina pectoris, myocardial infarction, arteriosclerosis, cerebrovascular disease and arrhythmia.
9. A method of preparing a compound of Formula 1, comprising:
(a) obtaining acetamide by mixing and reacting 2-chloroacetamide, N,N-dimethylformamide, potassium carbonate and a nucleophilic reagent in a reactor, terminating a reaction by addition of water, followed by concentrating;
(b) obtaining acetyl isocyanate by adding oxalyl chloride to the obtained acetamide, adding dichloroethane and heating and stirring, followed by concentrating; and
(c) obtaining a compound by adding methylene chloride to the obtained acetyl isocyanate, adding and reacting a nucleophilic reagent, followed by concentrating,
wherein
R1 is tetrazolyl, piperazinyl, morpholinyl, phenyl linked by O, or benzodioxolyl linked by O, wherein the tetrazolyl, piperazinyl, morpholinyl, phenyl, or benzodioxolyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of halogen, C1-6 haloalkyl, C1-6 alkoxy, phenyl, phenoxy, and —O—C2-20 alkylene-phenyl;
R2 is phenyl, pyridinyl, C2-20 alkylene-phenyl, C2-20 alkylene-indolyl, or C2-20 alkylene-dihydroindolyl, wherein the phenyl, pyridinyl, indolyl, or dihydroindolyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, —C1-6 alkoxy-C1-6 alkyl, —O-phenyl, and —O—C2-20 alkylene-phenyl; and
R3 and R4 are each independently hydrogen, C1-6 alkyl or C1-6 haloalkyl.
10. A method of preparing a compound of Formula 1, comprising:
(a) obtaining 2-chloroacetyl isocyanate by mixing 2-chloroacetamide and oxalyl chloride in a reactor, adding dichloroethane and heating and stirring, followed by concentrating;
(b) obtaining carbamoyl 2-chloroacetamide by adding methylene chloride to the obtained 2-chloroacetyl isocyanate, and then adding a nucleophilic reagent and reacting, followed by concentrating; and
(c) obtaining N-acylurea derivative by adding methanol to the obtained carbamoyl 2-chloroacetamide, adding and reacting a nucleophilic reagent while stirring, extracting an N-acylurea derivative using an organic solvent,
wherein
R1 is tetrazolyl, piperazinyl, morpholinyl, phenyl linked by O, or benzodioxolyl linked by O, wherein the tetrazolyl, piperazinyl, morpholinyl, phenyl, or benzodioxolyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of halogen, C1-6 haloalkyl, C1-6 alkoxy, phenyl, phenoxy, and —O—C2-20 alkylene-phenyl;
R2 is phenyl, pyridinyl, C2-20 alkylene-phenyl, C2-20 alkylene-indolyl, or C2-20 alkylene-dihydroindolyl, wherein the phenyl, pyridinyl, indolyl, or dihydroindolyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, —C1-6 alkoxy-C1-6 alkyl, —O-phenyl, and —O—C2-20 alkylene-phenyl; and
R3 and R4 are each independently hydrogen, C1-6 alkyl or C1-6 haloalkyl.
11. The method of claim 9 , wherein the nucleophilic reagent is selected from the group consisting of 4-bromo-3-methoxyanilin, 4-methoxybenzylamine, tryptamine, 2,4-dimethoxyaniline, 4-(benzyloxy)aniline, 2-fluoroaniline, Sesamol, 3-fluoropyridin-2-amine, 4-methoxyphenyl)methanamine, 4-(benzyloxy)aniline HCl, 2-methoxyphenol, 4-phenoxyaniline, 3,5-bis(trifluoromethyl)phenol, 3-bromophenol, 4-bromo-3-methoxyaniline, 2,3-dimethylphenol and 4-(benzyloxy)phenol.
12. The method of claim 10 , wherein the nucleophilic reagent is selected from the group consisting of 4-bromo-3-methoxyanilin, 4-methoxybenzylamine, tryptamine, 2,4-dimethoxyaniline, 4-(benzyloxy)aniline, 2-fluoroaniline, Sesamol, 3-fluoropyridin-2-amine, 4-methoxyphenyl)methanamine, 4-(benzyloxy)aniline HCl, 2-methoxyphenol, 4-phenoxyaniline, 3,5-bis(trifluoromethyl)phenol, 3-bromophenol, 4-bromo-3-methoxyaniline, 2,3-dimethylphenol and 4-(benzyloxy)phenol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/692,111 US20220194928A1 (en) | 2016-04-26 | 2022-03-10 | Novel n-acylurea derivative and composition comprising same for prevention or treatment of cardiovascular disease |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0050817 | 2016-04-26 | ||
KR1020160050817A KR101691954B1 (en) | 2016-04-26 | 2016-04-26 | Novel N-acylurea Derivatives and Composition for Prevention or Treatment of Cardiovascular Disorders Comprising the Same |
PCT/KR2016/015122 WO2017188551A1 (en) | 2016-04-26 | 2016-12-22 | Novel n-acylurea derivative and composition comprising same for prevention or treatment of cardiovascular disease |
US201816094826A | 2018-10-18 | 2018-10-18 | |
US17/692,111 US20220194928A1 (en) | 2016-04-26 | 2022-03-10 | Novel n-acylurea derivative and composition comprising same for prevention or treatment of cardiovascular disease |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/094,826 Continuation US11306073B2 (en) | 2016-04-26 | 2016-12-22 | N-acylurea derivative and composition comprising same for prevention or treatment of cardiovascular disease |
PCT/KR2016/015122 Continuation WO2017188551A1 (en) | 2016-04-26 | 2016-12-22 | Novel n-acylurea derivative and composition comprising same for prevention or treatment of cardiovascular disease |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220194928A1 true US20220194928A1 (en) | 2022-06-23 |
Family
ID=57810339
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/094,826 Active US11306073B2 (en) | 2016-04-26 | 2016-12-22 | N-acylurea derivative and composition comprising same for prevention or treatment of cardiovascular disease |
US17/692,111 Pending US20220194928A1 (en) | 2016-04-26 | 2022-03-10 | Novel n-acylurea derivative and composition comprising same for prevention or treatment of cardiovascular disease |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/094,826 Active US11306073B2 (en) | 2016-04-26 | 2016-12-22 | N-acylurea derivative and composition comprising same for prevention or treatment of cardiovascular disease |
Country Status (5)
Country | Link |
---|---|
US (2) | US11306073B2 (en) |
JP (1) | JP6686174B2 (en) |
KR (1) | KR101691954B1 (en) |
CN (1) | CN109153655B (en) |
WO (1) | WO2017188551A1 (en) |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4103018A (en) | 1976-10-12 | 1978-07-25 | Schering Corporation | 2-[4-(Polyhalo-2-hydroxy-2-propyl)anilino]-2-oxazolin-4-ones and thiazolin-4-ones corresponding thereto |
GB1574019A (en) | 1977-01-14 | 1980-09-03 | Joullie International Sa | Therapeutically useful 3,4,5-trimethoxybenzene derivatives |
ES472295A1 (en) * | 1978-08-02 | 1979-02-16 | Invest Tecnica Aplicada | New acylureas with pharmaceutical activity, the process for their preparation, and pharmaceutical compositions which contain them. |
CA1125170A (en) | 1978-12-07 | 1982-06-08 | Victor T. Bandurco | Quinazol in -2-ones |
ZA796623B (en) * | 1978-12-07 | 1981-07-29 | Ortho Pharma Corp | Substituted pyrrolo (1,2-c) quinazolines |
JPS5925980Y2 (en) | 1979-02-01 | 1984-07-28 | 株式会社クボタ | Direct-fired bathtub drain plug |
JPS5659755A (en) * | 1979-10-05 | 1981-05-23 | Invest Tecnica Aplicada | Acylurea compound* its manufacture and coagulation inhibitor containing it as main component |
US4490374A (en) | 1982-09-30 | 1984-12-25 | Ortho Pharmaceutical Corporation | 5,6-Dialkoxy-3,4-optionally substituted-2(1H)quinazolinones, composition and method of use |
CA2568609A1 (en) | 2003-05-28 | 2004-12-09 | Imotep Inc. | Haloethyl urea compounds and their use to attenuate, inhibit or prevent non-cancerous pathogenic cellular proliferation and diseases associated therewith |
JP2009532479A (en) | 2006-04-06 | 2009-09-10 | ノヴァカーディア,インク. | Simultaneous administration of adenosine A1 receptor antagonist and anticonvulsant |
US20080004282A1 (en) | 2006-04-10 | 2008-01-03 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
US8530621B2 (en) | 2007-01-12 | 2013-09-10 | The Regents Of The University Of California | Combined preparation of a thiazide diuretic and a loop diuretic |
US20090281322A1 (en) | 2008-05-08 | 2009-11-12 | Allergan, Inc. | THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS |
US20130023497A1 (en) | 2009-06-08 | 2013-01-24 | Chunlin Tao | Triazine Derivatives and their Therapeutical Applications |
WO2012047017A2 (en) * | 2010-10-05 | 2012-04-12 | 크리스탈지노믹스(주) | 2,3-dihydro-isoindol-1-one derivative and a composition comprising the same |
WO2014145029A2 (en) * | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
RU2769607C2 (en) * | 2013-03-15 | 2022-04-04 | ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | N-acyl-n'-(pyridin-2-yl)carbamides and their analogues exhibiting anticancer and antiproliferative activity |
EP3019171B1 (en) | 2013-07-11 | 2018-09-05 | Merck Sharp & Dohme Corp. | Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4) |
US9789096B2 (en) * | 2013-09-04 | 2017-10-17 | Board Of Regents Of The University Of Texas System | Methods and compositions for selective and targeted cancer therapy |
-
2016
- 2016-04-26 KR KR1020160050817A patent/KR101691954B1/en active IP Right Grant
- 2016-12-22 WO PCT/KR2016/015122 patent/WO2017188551A1/en active Application Filing
- 2016-12-22 CN CN201680086054.1A patent/CN109153655B/en active Active
- 2016-12-22 US US16/094,826 patent/US11306073B2/en active Active
- 2016-12-22 JP JP2018554715A patent/JP6686174B2/en active Active
-
2022
- 2022-03-10 US US17/692,111 patent/US20220194928A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN109153655A (en) | 2019-01-04 |
CN109153655B (en) | 2022-09-30 |
US20190119261A1 (en) | 2019-04-25 |
JP2019516673A (en) | 2019-06-20 |
WO2017188551A1 (en) | 2017-11-02 |
KR101691954B1 (en) | 2017-01-02 |
US11306073B2 (en) | 2022-04-19 |
JP6686174B2 (en) | 2020-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10351514B2 (en) | Benzimidazole inhibitors of the sodium channel | |
KR101471999B1 (en) | -3 gsk-3 inhibitors | |
ES2269709T3 (en) | CICLOALQUIL-UREA COMPOUNDS, FUSED WITH BENZO AND 1,4-DISPOSED GROUPS. | |
US9498475B2 (en) | Benzamides | |
Chinthala et al. | Synthesis, biological evaluation and molecular modeling studies of some novel thiazolidinediones with triazole ring | |
US8685971B2 (en) | Quinolinyloxyphenylsulfonamides | |
US20060293343A1 (en) | Pyrimidine derivatives | |
CZ2001559A3 (en) | Indoloxoacetylpiperazine derivatives exhibiting antiviral activity | |
SI9620092A (en) | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of her-2 autophosphorylation properties | |
JP2009535320A (en) | N- (2-thiazolyl) amide derivatives as GSK-3 inhibitors | |
JP2010536925A (en) | 4- (4-Pyridinyl) -benzamide and their use as ROCK activity modulators | |
US20040214880A1 (en) | Oxime derivatives and their use as pharmaceutically active agents | |
US20120095012A1 (en) | Toluidine sulfonamides and their use | |
BRPI0617364A2 (en) | heterocyclic compounds as pstat3 / il-6 inhibitors | |
JP2004506593A (en) | Cyclic amine derivatives and their uses | |
JP2013541493A (en) | Compounds useful as antiviral agents, compositions, and methods of use | |
Hagras et al. | Biphenylthiazole antibiotics with an oxadiazole linker: An approach to improve physicochemical properties and oral bioavailability | |
KR20100087300A (en) | Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof | |
KR20100075568A (en) | Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof | |
US20220194928A1 (en) | Novel n-acylurea derivative and composition comprising same for prevention or treatment of cardiovascular disease | |
Venkatachalam et al. | Effect of stereo and regiochemistry towards wild and multidrug resistant HIV-1 virus: viral potency of chiral PETT derivatives | |
US11530211B2 (en) | Dihydroindolizinone derivative | |
JPWO2003024950A1 (en) | Coumarin derivatives | |
US20170168073A1 (en) | Chalcone-urea derivatives as insulin sensors | |
NO315148B1 (en) | Use of unsubstituted and substituted N- (pyrrol-1-yl) pyridinamines as anticonvulsants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |